

Product Monograph
Including Patient Medication Information

PREVNAR 20™

Pneumococcal 20-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Suspension for Intramuscular Injection

One-Dose Syringe (0.5 mL)

Active Immunizing Agent (pneumococcal vaccine; ATC code: J07AL02)

Pfizer Canada ULC
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5

Date of Authorization:
September 29, 2025

Control Number: 299005

™Wyeth LLC

© Pfizer Canada ULC 2025

Recent Major Label Changes

None at time of the most recent authorization.

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Table of Contents	2
Part 1: Healthcare Professional Information.....	4
1. Indications.....	4
1.1. Pediatrics.....	4
1.2. Geriatrics.....	4
2. Contraindications	4
4. Dosage and Administration.....	4
4.1. Dosing Considerations	4
4.2. Recommended Dose and Dosage Adjustment	5
4.2.1. Pediatrics (6 Weeks Through 17 Years of Age)	5
4.2.2. Adults (18 Years of Age and Older).....	6
4.4. Administration	6
5. Overdose.....	7
6. Dosage Forms, Strengths, Composition, and Packaging	7
7. Warnings and Precautions	8
General	8
Driving and Operating Machinery	8
Hematologic	8
Immune	8
Reproductive Health.....	8
7.1. Special Populations.....	9
7.1.1. Pregnancy.....	9
7.1.2. Breastfeeding.....	9
7.1.3. Pediatrics.....	9
7.1.4. Geriatrics.....	9
8. Adverse Reactions	9

8.1.	Adverse Reaction Overview	9
8.2.	Clinical Trial Adverse Reactions	11
8.2.1.	Clinical Trial Adverse Reactions – Pediatrics.....	13
8.2.2.	Additional Information in Immunocompromised Patients in Studies with PREVNAR 13	16
8.3.	Less Common Clinical Trial Adverse Reactions	17
8.3.1.	Less Common Clinical Trial Adverse Reactions – Pediatrics	17
8.5.	Post-Market Adverse Reactions.....	18
9.	Drug Interactions.....	18
10.	Clinical Pharmacology.....	19
10.1.	Mechanism of Action	19
11.	Storage, Stability, and Disposal	19
12.	Special Handling Instructions	20
Part 2: Scientific Information		21
13.	Pharmaceutical Information	21
14.	Clinical Trials	21
14.1.	Clinical Trials by Indication	21
14.1.1.	Clinical Trials in Adults 18 Years of Age and Older	24
14.1.2.	Clinical Trials in Infants, Children and Adolescents 6 Weeks Through 17 Years of Age 25	
14.2.	Study Results.....	27
14.2.1.	Clinical Trials in Adults 18 Years of Age and Older	27
14.2.2.	Clinical Trials in Infants, Children and Adolescents 6 Weeks Through 17 Years of Age 30	
14.2.3.	Concomitant Vaccine Administration	36
14.3.	Clinical Studies of PREVNAR 13.....	37
16.	Non-Clinical Toxicology	39
Patient Medication Information		41

Part 1: Healthcare Professional Information

1. Indications

Infants, Children and Adolescents (6 Weeks Through 17 Years of Age)

PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) is indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Adults (18 Years of Age and Older)

PREVNAR 20 is indicated for active immunization of adults 18 years of age and older for the prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Clinical efficacy for the prevention of pneumonia was studied with PREVNAR 13 for the shared serotypes (see [14 Clinical Trials](#)), but not for the additional serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F.

PREVNAR 20 may not prevent disease caused by *S. pneumoniae* serotypes that are not contained in the vaccine.

1.1. Pediatrics

Based on the data submitted to and reviewed by Health Canada, the safety and efficacy of PREVNAR 20 in pediatric patients (6 weeks to <18 years of age) have been established. Therefore, Health Canada has authorized an indication for pediatric use in individuals 6 weeks through 17 years of age (prior to the 18th birthday). See [1 Indications](#), [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#) and [14 Clinical Trials](#).

1.2. Geriatrics

PREVNAR 20 has been studied in the geriatric population (see [7.1 Special Populations](#) and [14 Clinical Trials](#)).

2. Contraindications

PREVNAR 20 is contraindicated in individuals who are hypersensitive to the active substance or to any component of the vaccine, including diphtheria toxoid. For a complete listing see [6 Dosage Forms, Strengths, Composition, and Packaging](#).

4. Dosage and Administration

4.1. Dosing Considerations

- Individuals at higher risk of pneumococcal infection, including patients with sickle cell disease (SCD) or human immunodeficiency virus (HIV) infection, and those previously vaccinated with one or more doses of the 23-valent pneumococcal polysaccharide vaccine (PPSV23), are recommended to receive

at least one dose of PREVNAR 20 (see [7 Warnings and Precautions, Immune](#) and [14 Clinical Trials, PREVNAR 13 Immune Responses in Special Populations](#)).

- In individuals with a hematopoietic stem cell transplant (HSCT), the recommended immunization series with PREVNAR 20 consists of four doses of 0.5 mL. The primary series consists of three doses, with the first dose given 3 to 6 months after HSCT and with an interval of at least 1 month between doses. A booster dose is recommended 6 months after the third dose (see [7 Warnings and Precautions, Immune](#) and [14 Clinical Trials, PREVNAR 13 Immune Responses in Special Populations](#)).
- If the sequential use of PPSV23 is considered appropriate, PREVNAR 20 should be given first.

4.2. Recommended Dose and Dosage Adjustment

4.2.1. Pediatrics (6 Weeks Through 17 Years of Age)

It is recommended that infants who receive a first dose of PREVNAR 20 complete the vaccination series with PREVNAR 20.

Routine Vaccination Schedule for Infants and Toddlers 6 Weeks Through 15 Months of Age

4-Dose Series (3-Dose Primary Series Followed by a Toddler Dose)

The vaccination series consists of 4 doses of PREVNAR 20, each of 0.5 mL. The primary series consists of 3 doses, with the first dose usually given at 2 months of age (and as early as 6 weeks of age), with an interval of 4 to 8 weeks between doses. The fourth dose should be given between 11 and 15 months of age and at least 2 months after the third dose.

See [14.2.2 Clinical Trials in Infants, Children and Adolescents 6 Weeks Through 17 Years of Age](#) for the 3-Dose Series (2-Dose Primary Series Followed by a Toddler Dose)

Pre-term Infants (<37 Weeks Gestation at Birth)

The recommended vaccination series consists of 4 doses of PREVNAR 20, each of 0.5 mL. The primary series consists of 3 doses, with the first dose usually given at 2 months of age (and as early as 6 weeks of age), with an interval of 4 to 8 weeks between doses. The fourth dose should be given between 11 and 15 months of age and at least 2 months after the third dose.

Catch-up Vaccination Schedule for Unvaccinated Children and Adolescents 7 Months Through 17 Years of Age

Children 7 months through 17 years of age who have never received a pneumococcal conjugate vaccine may receive PREVNAR 20 according to the following schedules:

Infants 7 Through 11 Months of Age

Three doses of 0.5 mL, with the first 2 doses given at least 4 weeks apart. The third dose is given after the 1-year birthday, separated from the second dose by at least 2 months.

Children 12 Through 23 Months of Age

Two doses of 0.5 mL, with an interval of 2 months between doses.

Children and Adolescents 2 Through 17 Years of Age

One single 0.5 mL dose.

Catch-up Vaccination Schedule for Children Previously or Incompletely Vaccinated with PREVNAR 13

Children 15 months through 17 years of age who are considered completely immunized or with an incomplete vaccine series of PREVNAR 13 may receive 1 single 0.5 mL dose of PREVNAR 20. The catch-up (supplemental) dose of PREVNAR 20 should be administered with an interval of at least 8 weeks after the final dose of PREVNAR 13.

4.2.2. Adults (18 Years of Age and Older)

PREVNAR 20 is administered **intramuscularly** as a single 0.5 mL dose.


4.4. Administration

Do not mix PREVNAR 20 with any other vaccines or products in the same syringe.

Preparation for administration


Step 1. Vaccine resuspension

Hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the contents of the syringe are a homogeneous white suspension. Do not use the vaccine if it cannot be re-suspended.



Step 2. Visual inspection

Visually inspect the vaccine for large particulate matter and discoloration prior to administration. Do not use if large particulate matter or discoloration is found. If the vaccine is not a homogeneous white suspension, repeat steps 1 and 2.



Step 3. Remove syringe cap

Remove the syringe cap from the Luer lock adapter by slowly turning the cap counter-clockwise while holding the Luer lock adapter.



Note: Care should be taken to ensure that the extended plunger rod is not depressed while removing the syringe cap.

Step 4. Attach a sterile needle

Attach a needle appropriate for intramuscular administration to the pre-filled syringe by holding the Luer lock adapter and turning the needle clockwise.

Administration

For intramuscular use only.

Each 0.5 mL dose is to be injected intramuscularly, with care to avoid injection into or near nerves and blood vessels. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in children and adults. The vaccine should not be injected in the gluteal area.

Do not administer PREVNAR 20 intravascularly.

5. Overdose

Overdose with PREVNAR 20 is unlikely due to its presentation as a pre-filled syringe.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition, and Packaging

PREVNAR 20 is a homogeneous white suspension for intramuscular injection supplied in a single-dose pre-filled syringe. Each 0.5 mL dose of the vaccine is formulated to contain approximately 2.2 mcg of each of *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F saccharides, 4.4 mcg of 6B saccharide, 51 mcg CRM₁₉₇ carrier protein, 100 mcg polysorbate 80, 295 mcg succinic acid, 4.4 mg sodium chloride, and 125 mcg aluminum as aluminum phosphate adjuvant.

PREVNAR 20 is supplied in cartons of 1 and 10 single-dose pre-filled syringes, without needles.

The tip cap and plunger stopper of the pre-filled syringe are not made with natural rubber latex.

Table [1] – Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form/ Strength/Composition	Non-Medicinal Ingredients
Intramuscular	Suspension for injection 0.5 mL single-dose syringe	Aluminum phosphate Polysorbate 80 Sodium chloride Succinic acid Water for injection

To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.

Description

A white suspension for intramuscular injection, provided in a single-dose (0.5 mL), pre-filled syringe.

7. Warnings and Precautions

General

As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

As with other vaccines, the administration of PREVNAR 20 should be postponed in individuals suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

PREVNAR 20 will only protect against *Streptococcus pneumoniae* serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease or pneumonia.

As with any vaccine, PREVNAR 20 may not protect all individuals receiving the vaccine from pneumococcal disease.

Driving and Operating Machinery

PREVNAR 20 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under [8 Adverse Reactions](#) may temporarily affect the ability to drive or use machines.

Hematologic

As with all injectable vaccines, the vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.

Immune

Safety and immunogenicity data on PREVNAR 20 are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Studies in individuals with HIV, sickle cell disease and bone marrow transplant have not been conducted with PREVNAR 20; however, safety and immunogenicity studies with PREVNAR 13 are relevant to PREVNAR 20, since the vaccines are manufactured similarly and contain 13 of the same polysaccharide conjugates (see [14 Clinical Trials](#)).

Based on experience with pneumococcal vaccines, some individuals with altered immunocompetence may have reduced immune responses to PREVNAR 20. Individuals with impaired immune responsiveness, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunization. The clinical relevance of this is unknown.

Reproductive Health

- **Fertility**

No human data on the effect of PREVNAR 20 on fertility are available.

Animal studies do not indicate direct or indirect harmful effects with respect to female fertility or reproductive toxicity (see [16 Non-Clinical Toxicology](#)).

7.1. Special Populations

7.1.1. Pregnancy

Safety during pregnancy has not been established in humans.

7.1.2. Breastfeeding

Safety during lactation has not been established in humans.

It is not known whether vaccine antigens or antibodies are excreted in human milk.

7.1.3. Pediatrics

As with all injectable pediatric vaccines, the potential risk of apnea should be considered when administering the primary immunization series to preterm infants. The need for monitoring for at least 48 hours after vaccination should be considered for every preterm infant born ≤ 28 weeks of gestation who remains hospitalized at the time of the recommended administration. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

The effectiveness of PREVNAR 20 for the prevention of pneumonia has not been established in individuals younger than 18 years of age.

The safety and effectiveness of PREVNAR 20 in children younger than 6 weeks of age have not been established.

7.1.4. Geriatrics

Of the 4,263 adults in the three Phase 3 studies of the clinical development program who received PREVNAR 20, 668 (15.7%) were 65 through 69 years of age, 398 (9.3%) were 70 through 79 years of age, and 72 (1.7%) were 80 years of age and older. PREVNAR 20 has been shown to be safe and immunogenic in the geriatric population regardless of prior pneumococcal vaccination (see [14 Clinical Trials](#)).

8. Adverse Reactions

8.1. Adverse Reaction Overview

Adults 18 Years of Age and Older

The safety profile is based on the analysis of three Phase 3 clinical trials (see [14 Clinical Trials](#)). There were 4,263 adult participants who received PREVNAR 20, which included 3,639 adults that were naïve to pneumococcal vaccines, 253 that had previously received the 23-valent pneumococcal polysaccharide vaccine, (Pneumovax® 23 [PPSV23]) only, 246 that had previously received PREVNAR 13 only, and 125 that had previously received both PPSV23 and PREVNAR 13. The most commonly reported solicited adverse reactions ($>10\%$) were vaccination-site pain/tenderness, muscle pain, fatigue, headache and joint pain. Overall, the serious adverse events (SAEs) reported were consistent with diseases and conditions observed in adults of different age groups, and none were considered to be related to the study vaccine. In all three Phase 3 trials, PREVNAR 20 demonstrated a tolerability and safety profile similar to that of PREVNAR 13.

Infants, Children and Adolescents 6 Weeks Through 17 Years of Age

The safety of PREVNAR 20 was evaluated in 5,987 participants 6 weeks through 17 years of age in four randomized, double-blind, active-controlled clinical trials and one single-arm clinical trial (one Phase 2 and four Phase 3 trials); 3,664 participants received at least 1 dose of PREVNAR 20, and 2,323 participants received PREVNAR 13 (control vaccine). Across all 5 trials, there were similar percentages of male and female participants among the PREVNAR 20 recipients and the PREVNAR 13 recipients. Overall, 83.5% of PREVNAR 20 recipients were White, 7.9% Black, 1.6% Asian, and 24.0% Hispanic, with similar distribution among PREVNAR 13 recipients.

Infants and Children 6 Weeks to <15 Months of Age

Clinical trials were conducted in healthy infants and children 6 weeks to <15 months of age using a 3-dose series (Phase 3 Study 1012) or a 4-dose series (Phase 3 Studies 1011 and 1013 and Phase 2 Study 1003). In these 4 infant trials 5,156 participants received at least 1 dose of vaccine: 2,833 received PREVNAR 20 and 2,323 received PREVNAR 13. Overall, approximately 90% of participants in each group received all doses through the study-specified toddler dose. In all studies, local reactions and systemic events were collected after each dose, and adverse events were collected from the first dose through 1 month after the last infant vaccination and from the toddler dose through 1 month after the toddler dose in all studies. Serious adverse events were evaluated through 1 month after the last dose in Study 1012 and 6 months after the last dose in Studies 1011, 1013, and 1003.

PREVNAR 20 was well tolerated when administered on a 3-dose and a 4-dose series in the infant study populations, with low rates of severe local reactions and systemic events, and most reactions resolving within 1 to 3 days. The percentages of participants with reactogenicity events after PREVNAR 20 were generally similar to those after PREVNAR 13. Based on the infant data, the most frequently reported local reactions and systemic events after any dose of PREVNAR 20 were irritability, drowsiness, and pain at injection site. In these studies, PREVNAR 13 was co-administered or permitted to be administered with certain routine pediatric vaccines (see [14.2.3 Concomitant Vaccine Administration](#)).

Study 1012 was a double-blind, active-controlled Phase 3 trial, in which 601 healthy infants, 2 months (≥ 42 to ≤ 112 days) of age and born at >36 weeks of gestation received PREVNAR 20 in a 3-dose series. The most frequently reported adverse reactions ($>10\%$) after any dose of PREVNAR 20 were irritability (71.0% to 71.9%), drowsiness/increased sleep (50.9% to 61.2%), pain at injection site (22.8% to 42.4%), decreased appetite (24.7% to 39.3%), redness at injection site (25.3% to 36.9%), swelling at injection site (21.4% to 29.8%) and fever of $\geq 38.0^\circ\text{C}$ (8.9% to 24.3%). Most adverse reactions occurred within 1 to 2 days following vaccination and were mild to moderate in severity and of short duration (1 to 2 days).

Studies 1011, 1013 and 1003 were double-blind, randomized, active-controlled trials that included 2,232 healthy infants vaccinated with PREVNAR 20 in a 4-dose series. The most frequently reported adverse reactions ($>10\%$) observed after any dose of PREVNAR 20 in infants were irritability (58.5% to 70.6%), drowsiness/increased sleep (37.7% to 66.2%), pain at injection site (32.8% to 45.5%), decreased appetite (23.0% to 26.4%), redness at injection site (22.6% to 24.5%) and swelling at injection site (15.1% to 17.6%). Most adverse reactions were mild or moderate following vaccination and severe reactions were reported infrequently. In Study 1013, the local reactions and systemic events in the preterm subgroup (111 infants born at 34 to <37 weeks of gestation) were similar to or lower than the term infants in the study. In the preterm subgroup the frequency of any reported local reaction (31.7% to 55.3% in the PREVNAR 20 group and 37.9% to 47.1% in the PREVNAR 13 group) and systemic event (65.0% to 85.5% in the PREVNAR 20 group and 59.4% to 77.4% in the PREVNAR 13 group) were similar

after PREVNAR 20 and PREVNAR 13. Most adverse reactions occurred within 1 to 2 days following vaccination and were mild to moderate in severity and of short duration (1 to 3 days).

The frequency and severity of the adverse reactions in all infant clinical trials were generally similar in the PREVNAR 20 and PREVNAR 13 groups.

Children and Adolescents 15 Months through 17 Years of Age

In Phase 3 Study 1014, 831 participants 15 months through 17 years of age received a single dose of PREVNAR 20 in four age groups (209 participants 15 to <24 months of age; 216 participants 2 years to <5 years of age; 201 participants 5 years to <10 years age; and 205 participants 10 years to <18 years of age). The participants <5 years of age had received at least 3 prior doses of PREVNAR 13.

The most frequently reported adverse reactions (>10%) observed after any dose of PREVNAR 20 in participants <2 years of age were irritability (61.8%), pain at injection site (52.5%), drowsiness/increased sleep (41.7%), redness at injection site (37.7%), decreased appetite (25.0%), swelling at injection site (22.1%) and fever $\geq 38.0^{\circ}\text{C}$ (11.8%). In participants aged 2 years and older, the most frequently reported adverse reactions were pain at injection site (66.0% to 82.9%), muscle pain (26.5% to 48.3%), redness at injection site (15.1% to 39.1%), fatigue (27.8% to 37.2%), headache (5.6% to 29.3%), and swelling at injection site (15.6% to 27.1%). Most adverse reactions occurred within 1 to 2 days following vaccination and were mild to moderate in severity and of short duration (1 to 3 days).

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Adults 18 Years of Age and Older

Solicited Adverse Reactions

The frequency of solicited adverse reactions in adults <65 years of age naïve to pneumococcal vaccination and in adults ≥ 65 years of age by prior pneumococcal vaccination status are shown in Table 2 and Table 3, respectively. Local adverse reactions (redness, swelling, and pain at the injection site) were prompted daily for 10 consecutive days after vaccination. Systemic adverse events (fever, fatigue, headache, muscle pain, and joint pain) were prompted daily for 7 days after vaccination.

In general, the median onset day for local reactions was between Day 1 (day of vaccination) to Day 2.5, and they resolved with a median duration of 1 to 2 days. The median onset day for most systemic events was generally between Day 1 to Day 3.5, and they resolved with a median duration of 1 to 2 days.

Table 2. Solicited Local Adverse Reactions and Systemic Events After Vaccination in Pneumococcal Vaccine Naïve Adults <65 Years of Age from Studies 1007 and 1008

Adverse Reaction ^b	Study 1007 60-64 Years of Age		Study 1007 50-59 Years of Age		Study 1007 and Study 1008 18-49 Years of Age	
	PREVNAR 20 (N ^a =991) %	PREVNAR 13 (N ^a =990) %	PREVNAR 20 (N ^a =331) %	PREVNAR 13 (N ^a =111) %	PREVNAR 20 (N ^a =1791) %	PREVNAR 13 (N ^a =355) %
Local Reaction						
Redness	7.1	6.3	8.2	5.4	7.4	7.3
Swelling	8.0	8.3	8.8	10.8	9.1	9.9
Pain at injection site	61.6	59.2	72.5	69.4	79.2	77.7
Systemic Event						
Fever ≥38.0°C	0.8	0.4	1.5	0.9	1.2	1.1
Fever >40.0°C	0.2	0	0.3	0	0	0
Fatigue	32.7	32.4	39.3	36.0	46.7	43.7
Headache	24.5	25.3	32.3	36.0	36.7	36.6
Muscle pain	42.8	39.8	49.8	49.5	62.9	64.8
Joint pain	12.2	14.5	15.4	20.7	16.2	15.2

a. N = number of participants with any e-diary data reported after vaccination.

b. Local reactions solicited within 10 days after vaccination; systemic events solicited within 7 days after vaccination.

Table 3. Solicited Local Adverse Reactions and Systemic Events After Vaccination in Adults ≥65 Years of Age by Prior Pneumococcal Vaccination Status from Studies 1006 and 1007

Adverse Reaction ^b	Study 1007		Study 1006				
	Prior Pneumococcal Vaccination Status ^c						
	Naïve		PPSV23		PREVNAR 13		PREVNAR 13 & PPSV23
	PREVNAR 20 (N ^a =514) %	PREVNAR 13 (N ^a =493) %	PREVNAR 20 (N ^a =253) %	PREVNAR 13 (N ^a =121) %	PREVNAR 20 (N ^a =245) %	PPSV23 (N ^a =126) %	PREVNAR 20 (N ^a =125) %
Local Reaction							
Redness	7.8	6.1	7.9	2.5	8.6	12.7	4.8
Swelling	6.6	7.3	9.9	6.6	9.4	14.3	4.0
Pain at injection site	43.6	44.0	50.2	43.0	61.2	56.3	52.8
Systemic Event							
Fever ≥38.0°C	1.2	1.6	0.8	0	0	1.6	0
Fever >40.0°C	0.6	0.6	0	0	0	0	0
Fatigue	25.3	27.2	28.9	22.3	31.0	33.3	32.8
Headache	15.8	19.3	17.8	18.2	13.5	21.4	19.2
Muscle pain	31.9	32.3	32.0	31.4	33.9	46.0	37.6
Joint pain	13.4	12.0	6.7	10.7	11.8	15.9	16.8

Table 3. Solicited Local Adverse Reactions and Systemic Events After Vaccination in Adults ≥65 Years of Age by Prior Pneumococcal Vaccination Status from Studies 1006 and 1007

Adverse Reaction ^b	Study 1007		Study 1006				
	Prior Pneumococcal Vaccination Status ^c						
	Naïve		PPSV23		PREVNAR 13		PREVNAR 13 & PPSV23
	PREVNAR 20 (N ^a =514) %	PREVNAR 13 (N ^a =493) %	PREVNAR 20 (N ^a =253) %	PREVNAR 13 (N ^a =121) %	PREVNAR 20 (N ^a =245) %	PPSV23 (N ^a =126) %	PREVNAR 20 (N ^a =125) %

a. N = number of participants with any e-diary data reported after vaccination.

b. Local reactions solicited within 10 days after vaccination; systemic events solicited within 7 days after vaccination.

c. Includes participants who previously received either PPSV23 ≥1 to ≤5 years before enrollment (PPSV23), PREVNAR 13 ≥6 months before enrollment (PREVNAR 13), or PREVNAR 13 followed by PPSV23 ≥1 year before enrollment (PREVNAR 13 and PPSV23) in the study.

Safety with Concomitant Vaccine Administration in Adults

In Study 1004, the frequency of all solicited systemic ARs within 7 days following coadministration of PREVNAR 20 and influenza vaccine, adjuvanted (QIV) was numerically higher when coadministered compared to when given separately. Following the coadministration, the most frequently reported systemic ARs were fatigue (33.2%), followed by headache (21.9%), muscle pain (19.7%), and joint pain (13.3%), with most cases being mild to moderate (≤0.9% were severe) and having an onset time and duration similar to those following administration of PREVNAR 20 or influenza vaccine alone. Occurrence of fever was low in the coadministration group (1.5%), PREVNAR 20-only group (0.5%), and the influenza vaccine-only group (0.6%). No other difference in the safety profile between coadministration and separate administration for each of these vaccines alone was observed.

In study 1026, the frequency of all solicited systemic ARs (fatigue, headache, chills, muscle pain, and joint pain) except fever within 7 days after vaccination in the coadministration group was similar to that in the COVID-19 mRNA vaccine-only group but noticeably higher than that in the PREVNAR 20-only group. The most frequent systemic ARs in the coadministration group were fatigue (54.1%), followed by muscle pain (32.4%), headache (30.3%), chills (26.5%), and joint pain (26.5%). Fever (13.0%) and use of antipyretic or pain medication (34.6%) in the coadministration group were higher than those in both the PREVNAR 20-only group (1.1% and 15.1%, respectively), and the COVID-19 mRNA vaccine-only group (8.6% and 28.6%, respectively). The frequency of solicited ARs with moderate severity (33.0% for fatigue, 11.9% for headache, and 11.4% for joint pain) in the coadministration group was higher than that in both the PREVNAR 20-only group (12.4% for fatigue, 2.7% for headache, and 3.8% for joint pain), and the COVID-19 mRNA vaccine-only group (24.9% for fatigue, 7.6% for headache, and 9.7% for joint pain). No other apparent difference in the safety profile between the coadministration group, and the Pevnar 20-only group or the COVID-19 mRNA vaccine-only group was observed.

8.2.1. Clinical Trial Adverse Reactions – Pediatrics

Children 6 Weeks Through 17 Years of Age

Infants and Toddlers Receiving a Routine Vaccination Schedule

The percentages of infants and toddlers with solicited local reactions and systemic events that occurred within 7 days after each dose of PREVNAR 20 or PREVNAR 13 following a 3-dose or 4-dose series are shown in Tables 4 and 5, respectively.

Study 1012 (Table 4) evaluated a 3-dose series of either PREVNAR 20 or PREVNAR 13 with a first dose given at 42 to 112 days of age, a second dose approximately 2 months later, and the third dose at 11 to 12 months of age. Participants received concomitant vaccines at these visits (see [14.2.3 Concomitant Vaccine Administration](#)).

Studies 1003, 1011 and 1013 evaluated a 4-dose series of either PREVNAR 20 or PREVNAR 13 given at approximately 2, 4, 6, and 12 to 15 months of age (12 months of age for Study 1003). Participants received concomitant vaccines at these visits (see [14.2.3 Concomitant Vaccine Administration](#)). Table 5 presents pooled data from these 3 studies.

Table 4. Solicited Local Reactions and Systemic Events Within 7 Days After Each Dose in Infants Receiving a 3-Dose Series (Study 1012)

Dose	Dose 1		Dose 2		Dose 3 (Toddler Dose)	
	PREVNAR 20 (N ^a =598) %	PREVNAR 13 (N ^a =603) %	PREVNAR 20 (N ^a =592) %	PREVNAR 13 (N ^a =594) %	PREVNAR 20 (N ^a =580) %	PREVNAR 13 (N ^a =586) %
Local Reaction						
Pain at injection site ^c						
Any	29.1	29.4	22.8	24.6	42.4	39.9
Moderate	12.0	11.4	9.3	7.9	17.4	17.2
Severe	0.3	0	0.2	0.2	0.3	0.3
Redness ^b						
Any	25.3	27.5	28.5	28.1	36.9	33.8
Moderate	4.5	4.8	3.7	5.1	13.4	8.5
Severe	0	0	0	0.2	0.2	0.2
Swelling ^b						
Any	21.4	20.2	22.0	20.5	29.8	24.6
Moderate	8.7	7.3	8.3	6.2	11.9	9.7
Severe	0	0	0	0.2	0.2	0.3
Systemic Event						
Irritability	71.9	72.5	71.6	68.4	71.0	70.8
Drowsiness	61.2	63.7	51.4	50.7	50.9	48.6
Decreased appetite	24.7	22.6	24.7	19.4	39.3	36.5
Fever						
Any (≥38.0°C)	8.9	8.5	14.9	14.0	24.3	23.7
>38.9 to 40°C	0	0.3	0.7	0.3	3.6	3.2
>40.0°C	0	0	0	0	0.3	0

a. N = number of participants with any e-diary data reported after vaccination. This value is the denominator for percentage calculations.

b. Any: >0.0 cm; Moderate: >2.0 to 7.0 cm; severe: >7.0 cm.

c. Any: any pain at injection site; Moderate: hurts if gently touched with crying; Severe: causes limitation of arm movement.

Table 5. Solicited Local Reactions and Systemic Events Within 7 Days After Each Dose in Infants Receiving a 4-Dose Primary Series (Studies 1003, 1011, 1013)

Dose	Dose 1		Dose 2		Dose 3		Dose 4 (Toddler Dose)	
	PREVNAR 20 (N ^a =2214) %	PREVNAR 13 (N ^a =1696) %	PREVNAR 20 (N ^a =2107) %	PREVNAR 13 (N ^a =1613) %	PREVNAR 20 (N ^a =2055) %	PREVNAR 13 (N ^a =1582) %	PREVNAR 20 (N ^a =1904) %	PREVNAR 13 (N ^a =1454) %
Local Reaction								

Pain at injection site ^c								
Any	45.5	45.4	38.6	39.9	32.8	35.5	33.4	34.6
Moderate	17.1	15.8	13.1	14.0	11.0	12.4	10.5	8.9
Severe	0.2	0	0.4	0.2	0.1	0	0.5	0
Redness ^b								
Any	23.8	23.2	23.5	25.7	24.5	25.0	22.6	25.6
Moderate	3.7	2.5	2.6	3.7	3.7	3.5	4.6	4.0
Severe	0	0	0	0	0	0.1	0.1	0
Swelling ^b								
Any	17.6	17.6	16.7	18.0	16.8	17.5	15.1	16.0
Moderate	5.1	4.1	4.2	4.5	4.0	3.5	4.3	3.2
Severe	0.1	0	0	0	0	0.2	0	0
Systemic Event								
Irritability	70.6	71.5	68.4	69.9	60.8	61.4	58.5	59.4
Drowsiness	66.2	65.6	52.4	54.1	39.8	41.9	37.7	38.1
Decreased appetite	24.8	24.7	24.9	23.1	23.0	22.3	26.4	25.9
Fever								
Any (≥38.0°C)	10.3	8.5	16.5	15.7	12.7	13.1	16.0	15.0
>38.9 to 40°C	0.7	0.4	1.9	1.6	1.6	1.8	3.2	3.0
>40.0°C	0	0	0.1	0	0	0	0.2	0.1

a. N = number of participants with any e-diary data reported after vaccination. This value is the denominator for percentage calculations.

b. Any: >0.0 cm; Moderate: >2.0 to 7.0 cm; severe: >7.0 cm.

c. Any: any pain at injection site; Moderate: hurts if gently touched with crying; Severe: causes limitation of arm movement

Safety with Concomitant Vaccine Administration in Infants and Toddlers

The safety profile of PREVNAR 20 was acceptable, and similar to PREVNAR 13 when administered concomitantly with routine pediatric vaccines containing diphtheria, tetanus, acellular pertussis, hepatitis B virus, poliovirus, and *Haemophilus influenzae* type b antigens; measles, mumps, and rubella antigens; and varicella antigens (see [14.2.3 Concomitant Vaccine Administration](#)).

Children 15 Months Through 17 Years of Age

Study 1014 evaluated the safety of a single dose of PREVNAR 20 in children 15 months through 17 years of age. The percentages of children (by age group) with solicited local reactions and systemic events that occurred within 7 days after a dose of PREVNAR 20 or PREVNAR 13 are shown in Table 6. The types of solicited systemic events collected in the participants 15 months to <2 years of age were consistent with those collected in infants, while the solicited systemic events in children ≥2 years of age required verbal communication by the participant.

Table 6. Solicited Local Reactions and Systemic Events Within 7 Days After Vaccination in Participants 15 Months Through 17 Years of Age (Study 1014)

Age	15 to <24 Months	2 to <5 Years	5 to <10 Years	10 to <18 Years
	PREVNAR 20 (N ^a =204)	PREVNAR 20 (N ^a =215)	PREVNAR 20 (N ^a =199)	PREVNAR 20 (N ^a =205)
	%	%	%	%
Local Reaction				
Redness ^b				
Any	37.7	39.1	37.2	15.1
Moderate	7.4	15.3	18.6	3.9

Severe	0	0.9	2.0	0.5
Swelling ^b				
Any	22.1	23.3	27.1	15.6
Moderate	6.4	11.2	15.6	10.2
Severe	0	0.5	1.0	0
Pain at injection site ^c				
Any	52.5	66.0	82.9	82.0
Moderate	9.8	17.7	24.6	17.6
Severe	1.0	1.4	1.5	1.5
Systemic Event^d				
Fever				
Any ($\geq 38.0^{\circ}\text{C}$)	11.8	3.3	0.5	0
>38.9 to 40°C	2.9	0.5	0	0
> 40.0°C	0	0	0	0
Decreased appetite	25.0	-	-	-
Drowsiness/increased sleep	41.7	-	-	-
Irritability	61.8	-	-	-
Fatigue	-	37.2	28.1	27.8
Headache	-	5.6	18.6	29.3
Muscle pain	-	26.5	39.2	48.3
Joint pain	-	3.7	6.5	8.3

a. N = number of participants with any e-diary data reported after vaccination. This value is the denominator for percentage calculations.

b. Any: >0.0 cm; Moderate: >2.0 to 7.0 cm; severe: >7.0 cm.

c. For participants 15 months to <24 months of age: Any: any pain at injection site; Moderate: hurts if gently touched with crying; Severe: causes limitation of arm movement. For participants 2 years to <18 years of age: Any: any pain at injection site; Moderate: interferes with activity; Severe: prevents daily activity.

d. For participants 15 months to <24 months of age, solicited systemic events were fever, decreased appetite, drowsiness/increased sleep and irritability. For participants 2 years to <18 years of age, solicited systemic events were fever, fatigue, headache, muscle pain and joint pain.

8.2.2. Additional Information in Immunocompromised Patients in Studies with PREVNAR 13

Children and adolescents 6 through 17 years of age with SCD, HIV infection or HSCT who received PREVNAR 13 had similar frequencies of adverse reactions as children and adolescents 2 through 17 years of age who received PREVNAR 13, except vaccination-site pain causing limitation of limb movement, joint pain, fever, headache, vomiting, diarrhea, fatigue and muscle pain had a frequency category of very common ($\geq 1/10$).

Adults 18 years and older with HIV infection who received PREVNAR 13 had similar frequencies of adverse reactions as adults 18 years of age and older who received PREVNAR 13, except that fever and vomiting had a frequency category of Very Common ($\geq 1/10$) and nausea had a frequency category of Common ($\geq 1/100$ to $<1/10$).

Adults 18 years and older with a HSCT who received PREVNAR 13 had similar frequencies of adverse reactions as adults 18 years and older who received PREVNAR 13, except that fever, diarrhea and vomiting had a frequency category of Very Common ($\geq 1/10$).

8.3. Less Common Clinical Trial Adverse Reactions

Adults 18 Years of Age and Older

Listed below are the less common adverse reactions reported in adult clinical trials with PREVNAR 20 (Uncommon frequency $\geq 1/1,000$ to $< 1/100$).

Immune system disorders: Hypersensitivity reaction, including face edema, dyspnea, bronchospasm

Gastrointestinal disorders: Diarrhea, nausea, vomiting

Skin and subcutaneous tissue disorders: Rash, angioedema

General disorders and administration site conditions: Vaccination-site pruritus, lymphadenopathy, vaccination-site urticaria, chills

8.3.1. Less Common Clinical Trial Adverse Reactions – Pediatrics

Less common adverse reactions reported in children 6 weeks to < 5 years of age in PREVNAR 20 pediatric clinical trials included vomiting (1.4%), diarrhea (1.0%), rash (1.0%), urticaria or urticaria-like rash (0.5%), seizures (including febrile seizures) (0.4%) and vaccination site hypersensitivity ($< 0.1\%$).

Less common adverse reactions reported in the PREVNAR 20 pediatric clinical in children 5 to < 18 years of age included urticaria or urticaria-like rash (0.5%).

Additionally, as PREVNAR 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine excipients as PREVNAR 13, the adverse reactions already identified and listed below for PREVNAR 13 have been adopted for PREVNAR 20. In clinical trials, the safety profile of PREVNAR 20 was similar to that of PREVNAR 13. The frequencies below are defined as follows: very common ($\geq 10\%$), common ($\geq 1\%$ to $< 10\%$), uncommon ($\geq 0.1\%$ to $< 1\%$), and rare ($\geq 0.01\%$ to $< 0.1\%$). For the following adverse reactions reported only for PREVNAR 13 in clinical trials, but not also reported in PREVNAR 20 clinical trials, the frequency is unknown for PREVNAR 20.

Adverse reactions reported for infants and children 6 weeks to < 5 years of age in PREVNAR 13 clinical trials:

Immune system disorders: Hypersensitivity reaction, including face edema, dyspnea, bronchospasm (rare)

Nervous system disorders: Hypotonic-hyporesponsive episode (rare), restless sleep/decreased sleep (very common)

Psychiatric disorders: Crying (uncommon)

Adverse reactions reported for children and adolescents 5 years to < 18 years of age in PREVNAR 13 clinical trials:

Gastrointestinal disorders: Diarrhea (common), vomiting (common)

Metabolism and nutrition disorders: Decreased appetite (very common)

Nervous system disorders: Drowsiness/increased sleep (very common), restless sleep/decreased sleep (very common)

Psychiatric disorders: Irritability (very common)

Skin and subcutaneous tissue disorders: Rash (common)

8.5. Post-Market Adverse Reactions

Post-marketing Experience with PREVNAR 13

The following adverse reactions have been reported since market introduction of PREVNAR 13, and are included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to PREVNAR 13. These adverse reactions reported in the post-marketing experience of PREVNAR 13 in pediatric and adult populations may also be seen in post-marketing experience with PREVNAR 20 as the components of PREVNAR 13 are also contained in PREVNAR 20.

Table 7. Adverse Reactions From PREVNAR 13 Post-marketing Experience

System Organ Class	Frequency Not Known
Blood and lymphatic system disorders	Lymphadenopathy localized to the region of the vaccination-site
Immune system disorders	Anaphylactic/anaphylactoid reaction including shock
Skin and subcutaneous tissue disorders	Angioedema, erythema multiforme
General disorders and administration site conditions	Vaccination-site dermatitis, vaccination-site pruritus, vaccination-site urticaria

9. Drug Interactions

If PREVNAR 20 is administered at the same time as another injectable vaccine, the vaccines should always be administered with different syringes and given at different injection sites.

Do not mix PREVNAR 20 with other vaccines/products in the same syringe.

Adults

PREVNAR 20 can be administered concomitantly with influenza vaccine, adjuvanted quadrivalent (QIV) or with COVID-19 mRNA vaccine (see [14 Clinical Trials, Concomitant vaccine administration](#)).

Infants and Children 6 Weeks To <5 Years of Age

In infants and children 6 weeks to <5 years of age, PREVNAR 20 can be administered concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular pertussis, *Haemophilus influenzae* type b, inactivated poliomyelitis, hepatitis B, measles, mumps, rubella (MMR) and varicella vaccines. The vaccine has been safely administered with influenza and rotavirus vaccine.

There are no data on the concomitant administration of PREVNAR 20 with other vaccines.

10. Clinical Pharmacology

10.1. Mechanism of Action

S. pneumoniae (pneumococcus) is a gram-positive diplococcus that can cause invasive disease including meningitis, sepsis, and pneumonia with bacteremia and non-invasive disease such as pneumonia without bacteremia. Non-bacteremic pneumococcal pneumonia accounts for the majority of pneumococcal disease cases among the adult population. Over 100 different serotypes of pneumococcus have been identified. The serotypes included in PREVNAR 20 were selected based on their relevance in causing global disease and have been associated with higher case fatality rates and mortality, antibiotic resistance, meningitis and outbreaks.

PREVNAR 20 contains 20 pneumococcal capsular polysaccharides all conjugated to CRM₁₉₇ carrier protein, which modifies the immune response to the polysaccharide from a T cell independent response to a T cell dependent response. The T-cell dependent response leads to a higher antibody response, and induces antibodies that enhance opsonisation, phagocytosis and killing of pneumococci to protect against pneumococcal disease, as well as generation of memory B cells, allowing for an anamnestic (booster) response on re-exposure to bacterial polysaccharide. In the absence of T-cell help, plain polysaccharide (PS) stimulated B-cells predominantly produce IgM antibodies; there is generally no affinity maturation of the antibodies, and no memory B-cells are generated. As vaccines, PSs are associated with poor or absent immunogenicity in infants less than 24 months of age and failure to induce immunological memory at any age.

Immune responses in children and adults following natural exposure to *S. pneumoniae* or following pneumococcal vaccination can be determined by measuring opsonophagocytic activity (OPA) and immunoglobulin G (IgG) responses. OPA represents functional antibodies and is considered an important immunologic surrogate measure of protection against pneumococcal disease in adults. In children, multiple immunogenicity criteria are used for the clinical evaluation of pneumococcal conjugate vaccines including the IgG antibody level of 0.35 mcg/mL using the World Health Organization (WHO) enzyme linked immunosorbent assay (ELISA) or equivalent assay-specific value. The levels of circulating antibodies in adults and the serotype-specific IgG levels in pediatric populations that correlate with protection against pneumococcal disease have not been clearly defined.

11. Storage, Stability, and Disposal

Store in a refrigerator between 2°C and 8°C (36°F to 46°F).

Syringes should be stored in the refrigerator horizontally to minimize the re-dispersion time.

Do not freeze. Discard if the vaccine has been frozen.

PREVNAR 20 should be administered as soon as possible after being removed from refrigeration.

PREVNAR 20 can be administered provided total (cumulative multiple excursions) time out of refrigeration (at temperatures between 8°C and 25°C) does not exceed 96 hours.

Cumulative multiple excursions between 0°C and 2°C are also permitted as long as the total time between 0°C and 2°C does not exceed 72 hours. These are not, however, recommendations for storage.

12. Special Handling Instructions

During storage, a white deposit and clear supernatant may be observed in the pre-filled syringe containing the suspension. Syringes should be stored horizontally to minimize the re-dispersion time.

Any unused product or waste material should be disposed of in accordance with local requirements.

Part 2: Scientific Information

13. Pharmaceutical Information

Drug Substance

PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) is a sterile suspension of saccharides of the capsular antigens of *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, each individually linked to non-toxic diphtheria CRM₁₉₇ protein.

Product Characteristics:

Each serotype is grown in soy peptone broth, and the individual polysaccharides are purified by a series of chemical and physical methods. The polysaccharides are chemically activated and then directly conjugated to the carrier protein CRM₁₉₇, to form the glycoconjugate. CRM₁₉₇ is a non-toxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β₁₉₇). The individual glycoconjugates are purified by a series of chemical and physical methods and compounded to formulate PREVNAR 20.

Each 0.5 mL dose of the vaccine is formulated to contain approximately 2.2 mcg of each of *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F saccharides, and 4.4 mcg of 6B saccharide, individually conjugated to CRM₁₉₇ carrier protein (approximately 51 mcg/dose) and adsorbed on aluminum phosphate (0.125 mg aluminum/dose).

14. Clinical Trials

14.1. Clinical Trials by Indication

Table 8. Summary of Patient Demographics for PREVNAR 20 Clinical Trials

Study #	Study design	Dosage, route of administration	Study subjects (n) ^a	Demographics
Adults 18 Years of Age and Older				
B7471007	Phase 3, multicenter, randomized, double-blind study with an age-based 3-cohort design	<u>Cohort 1:</u> One IM dose of 20vPnC/Saline or 13vPnC/PPSV23 (Vaccination 1/ Vaccination 2) <u>Cohorts 2 and 3:</u> One IM dose of 20vPnC or 13vPnC	<u>Cohort 1 (≥60 years)</u> 20vPnC/saline: 1507 13vPnC/PPSV23: 1490 <u>Cohort 2 (50-59 years)</u> 20vPnC: 334 13vPnC: 111 <u>Cohort 3 (18-49 years)</u> 20vPnC: 335 13vPnC: 112	<u>Cohort 1:</u> Sex: 1221 M/1776 F Age: mean (min/max): 64.6 (60/91) years <u>Cohort 2:</u> Sex: 181 M/264 F Age: mean (min/max): 54.9 (48 ^b /59) years <u>Cohort 3:</u> Sex: 156 M/291 F Age: mean (min/max): 34.0 (18/60 ^b) years

Table 8. Summary of Patient Demographics for PREVNAR 20 Clinical Trials

Study #	Study design	Dosage, route of administration	Study subjects (n) ^a	Demographics
B7471006	Phase 3, multicenter, randomized, open-label study with a 3-cohort design based on prior pneumococcal vaccination status	<u>Cohort A:</u> One IM dose of 20vPnC or 13vPnC <u>Cohort B:</u> One IM dose of 20vPnC or PPSV23 <u>Cohort C:</u> One IM dose of 20vPnC	<u>Cohort A:</u> (prior vaccination with PPSV23 $\geq$ 1 year and $\leq$ 5 years) 20vPnC: 253 13vPnC: 122 <u>Cohort B:</u> (prior vaccination with 13vPnC $\geq$ 6 months) 20vPnC: 246 13vPnC: 127 <u>Cohort C:</u> (prior vaccination with 13vPnC followed by PPSV23) 20vPnC: 125	<u>Cohort A:</u> Sex: 171 M/204 F Age: mean (min/max): 69.8 (65/84) years <u>Cohort B:</u> Sex: 167 M/206 F Age: mean (min/max): 70.7 (65/92) years <u>Cohort C:</u> Sex: 60 M/65 F Age: mean (min/max): 70.8 (65/81) years
B7471008	Phase 3, multicenter, randomized, double-blind, lot consistency study with a 4-arm parallel design	One IM dose of 20vPnC (Lot 1, 2 or 3) or 13vPnC	18-49 years, pneumococcal vaccine naïve Pooled 20vPnC: 1463 13vPnC: 245	<u>Pooled 20vPnC:</u> Sex: 492 M/971 F Age: mean (min/max): 35.4 (18/49) years <u>13vPnC:</u> Sex: 101 M/144 F Age: mean (min/max): 35.0 (18/49) years
Infants, Children and Adolescents 6 Weeks Through 17 Years of Age				
B7471011	Phase 3, multicenter, randomized, double-blind, active-controlled trial, using a schedule of 3 infant doses and a toddler dose	4 IM doses of 20vPnC or 13vPnC at 2, 4, 6, and 12–15 months of age; 3 doses of Pediarix and Hiberix coadministered with Doses 1-3 of 20vPnC or 13vPnC; 1 dose of M-M-R II and Varivax coadministered with Dose 4 of 20vPnC or 13vPnC	20vPnC: 1001 13vPnC: 990	<u>20vPnC:</u> Sex: 518 M / 483 F Age ^c mean (min, max): 65.9 (42, 97) days <u>13vPnC:</u> Sex: 505 M / 482 F Age ^c mean (min, max): 65.6 (43, 96) days

Table 8. Summary of Patient Demographics for PREVNAR 20 Clinical Trials

Study #	Study design	Dosage, route of administration	Study subjects (n) ^a	Demographics
B7471012	Phase 3, multicenter, randomized, double-blind, active-controlled trial, using a schedule of 2 infant doses and a toddler dose	3 IM doses of 20vPnC or 13vPnC at 2-3, 4-5, and 11-12 months of age; 3 doses of Infanrix hexa coadministered with Doses 1-3 of 20vPnC or 13vPnC; 1 dose of M-M-RVAXPRO and Varilrix coadministered with Dose 3 of 20vPnC or 13vPnC	20vPnC: 601 13vPnC: 603	<u>20vPnC:</u> Sex: 299 M / 302 F Age ^c mean (min, max): 69.2 (43, 112) days <u>13vPnC:</u> Sex: 311 M / 292 F Age ^c mean (min, max): 69.7 (43, 112) days
B7471013	Phase 3, multicenter, randomized, double-blind, active-controlled trial, using a schedule of 3 infant doses and a toddler dose	4 IM doses of 20vPnC or 13vPnC at 2, 4, 6, and 12–15 months of age	20vPnC: 1000 13vPnC: 504	<u>20vPnC:</u> Sex: 517 M / 483 F Age ^c mean (min, max): 64.0 (43, 98) days <u>13vPnC:</u> Sex: 244 M / 259 F Age ^c mean (min, max): 65.0 (43, 97) days

Table 8. Summary of Patient Demographics for PREVNAR 20 Clinical Trials

Study #	Study design	Dosage, route of administration	Study subjects (n) ^a	Demographics
B7471014	Phase 3, multicenter, single-arm trial of a single dose in children 15 months through 17 years of age with a 4-cohort design based on age	1 IM dose of 20vPnC	<u>Cohort 1 (15 to <24 months)</u> 20vPnC: 209 <u>Cohort 2 (2 to <5 years)</u> 20vPnC: 216 <u>Cohort 3 (5 to <10 years)</u> 20vPnC: 201 <u>Cohort 4 (10 to <18 years)</u> 20vPnC: 205	<u>Cohort 1</u> Sex: 117 M / 92 F Age mean (min, max): 18.3 (15, 24) months <u>Cohort 2</u> Sex: 106 M / 110 F Age mean (min, max): 3.0 (2, 4) years <u>Cohort 3</u> Sex: 108 M / 93 F Age mean (min, max): 7.2 (5, 9) years <u>Cohort 4</u> Sex: 115 M / 90 F Age mean (min, max): 13.6 (10, 17) years

Abbreviations: 20vPnC: PREVNAR 20; 13vPnC: PREVNAR 13; PPSV23: 23-valent pneumococcal polysaccharide vaccine; M: male; F: female

a. Number of subjects vaccinated.

b. One subject was incorrectly enrolled in Cohort 3 (18-49 years of age) rather than Cohort 1 (≥60 years of age), and one subject was incorrectly enrolled in Cohort 2 (50-59 years of age) rather than Cohort 3 (18-49 years of age).

c. Age (in days) at first dose. For participants randomized but not vaccinated, age is calculated using enrollment date instead of date at first dose.

14.1.1. Clinical Trials in Adults 18 Years of Age and Older

Three Phase 3 clinical trials (Study 1006, Study 1007, and Study 1008) were conducted in the United States and Sweden evaluating the safety and immunogenicity of PREVNAR 20 in adults of different age groups, including individuals who were either pneumococcal vaccine naïve (Studies 1007 and 1008) or who were previously vaccinated with PREVNAR 13, PPSV23, or both (Study 1006).

Each study included healthy adults and immunocompetent adults with stable underlying conditions including chronic cardiovascular disease, chronic pulmonary disease, renal disorders, diabetes mellitus, chronic liver disease, and medical risk conditions and behaviors (e.g., smoking) that are known to increase the risk of serious pneumococcal pneumonia and invasive pneumococcal disease (IPD).

In each study, immune responses elicited by PREVNAR 20 and the control pneumococcal vaccines were measured before and one month after vaccination by an opsonophagocytic activity (OPA) assay. Serotype-specific OPA assays measure functional antibodies to *S pneumoniae*, and OPA titer is the

reciprocal of the highest serum dilution resulting in 50% reduction in the number of bacterial colony forming units compared to control without serum.

Study 1007

The pivotal Study 1007 was a non-inferiority study consisting of a main Cohort 1 of participants 60 years of age and older, randomized (1:1) to receive a single dose of either PREVNAR 20 (Vaccination 1) followed 1 month later with administration of saline placebo (Vaccination 2), or PREVNAR 13 (Vaccination 1) followed 1 month later with a dose of PPSV23 (Vaccination 2). The other two younger cohorts, participants 50 through 59 years of age (Cohort 2) and participants 18 through 49 years of age (Cohort 3), were randomized (3:1) either to receive a single dose of PREVNAR 20 or PREVNAR 13.

Serotype-specific OPA geometric mean titers (GMTs) were measured before the first vaccination and one month after each Vaccination 1 or 2. In Cohort 1, non-inferiority of immune responses with PREVNAR 20 to a control vaccine (PREVNAR 13 or PPSV23) for each serotype OPA GMT on the natural log scale was declared if the lower bound of the 2 sided 95% confidence interval (CI) for the GMT ratio (geometric mean ratio; GMR) was greater than 0.5. A linear regression model that included terms for age, baseline OPA titer, sex, smoking status and vaccine group was used to calculate the GMRs. Similarly, the OPA titers from the younger Cohorts 2 and 3 were declared non-inferior to those from subjects aged 60 to 64 years from Cohort 1 for each PREVNAR 20 serotype, if the lower 2-sided 95% confidence limit for the serotype-specific OPA GMR exceeded 0.5.

Study 1006

Study 1006 described immune responses to PREVNAR 20 in adults 65 years of age and older previously vaccinated with PPSV23 between ≥ 1 to ≤ 5 years prior to enrollment (Cohort A), previously vaccinated with PREVNAR 13 ≥ 6 months prior to enrollment (Cohort B), and previously vaccinated with PREVNAR 13 followed by PPSV23 ≥ 1 year prior to enrollment (Cohort C). Participants in Cohorts A and B were randomized (2:1) to receive either a single dose of PREVNAR 20 or control pneumococcal vaccine (PREVNAR 13 or PPSV23, respectively). In Cohort C, participants only received a single dose of PREVNAR 20. There was no formal hypothesis testing for any safety or immunogenicity endpoint.

Study 1008

The safety and immunogenicity of three different lots of PREVNAR 20 were compared in pneumococcal vaccine naïve adults 18 through 49 years of age. Participants received a single dose of PREVNAR 20. The 3 different lots of PREVNAR 20 elicited equivalent immune responses for the 20 vaccine serotypes (data not shown).

14.1.2. Clinical Trials in Infants, Children and Adolescents 6 Weeks Through 17 Years of Age

Clinical studies evaluating the immunogenicity of PREVNAR 20 were conducted in infants following a 3-dose series at approximately 2 to 3, 4 to 5 and 11 to 12 months of age (2 infant doses and toddler dose) in a Phase 3 trial (Study 1012) or a 4 dose series (3 infant doses and a toddler dose) at approximately 2, 4, 6, and 12 to 15 months of age in one randomized Phase 2 trial (Study 1003) and one Phase 3 trial (Study 1011). One Phase 3 trial (Study 1014) of children 15 months through 17 years of age evaluated a single dose of PREVNAR 20.

Immunogenicity was assessed by serotype-specific IgG response rates (the proportion of participants meeting the serotype specific IgG level of ≥ 0.35 mcg/mL or equivalent assay-specific value) and IgG geometric mean concentrations (GMCs) at one month following the primary series and/or following the toddler dose. In a randomly selected subset of participants, OPA geometric mean titers (GMTs) were also measured at one month following the primary series and/or following the toddler dose. The

predefined IgG level is only applicable at the population level and cannot be used to predict individual or serotype-specific protection against IPD.

Immune responses elicited by PREVNAR 20 and PREVNAR 13 in children were measured using a serotype-specific multiplex direct-binding Luminex immunoassay (dLIA), designed to determine the concentration of specific polysaccharide-binding IgG antibodies, and opsonophagocytic activity (OPA) assays to measure serotype specific functional OPA titers. The Pfizer LUMINEX assay (dLIA) to measure IgG has been bridged to the standard ELISA assay.

In Study 1012, the immunogenicity of PREVNAR 20 was evaluated in infants when administered in a series of 2 infant doses and 1 toddler dose in infants enrolled from Europe and Australia. The study enrolled infants 2 months (≥ 42 to ≤ 112 days) of age and born at >36 weeks of gestation. Participants were randomized (1:1) to receive either PREVNAR 20 or PREVNAR 13 with the first dose given at 42 to 112 days of age, a second dose given approximately 2 months later, and the third dose given at approximately 11 to 12 months of age. Participants received concomitant vaccines at these visits (DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) with all 3 doses, MMR (M-M-RVAXPRO) and Varicella (Varilrix) vaccines with Dose 3).

In Study 1011, healthy infants 2 months (≥ 42 to ≤ 98 days) of age at the time of consent and born at >36 weeks of gestation were enrolled from the United States, including Puerto Rico. Participants were randomized (1:1) to receive a series of 3 infant doses and 1 toddler dose of either PREVNAR 20 or PREVNAR 13 at approximately 2, 4, 6, and 12 to 15 months of age. Routine pediatric vaccinations were administered concomitantly.

PREVNAR 20 elicited immune responses, as assessed by IgG GMCs, percentages of participants with predefined IgG concentrations, and OPA geometric mean titers (GMTs) for all 20 serotypes contained in the vaccine.

14.2. Study Results

14.2.1. Clinical Trials in Adults 18 Years of Age and Older

Study 1007

Comparison of immune responses of PREVNAR 20 to PREVNAR 13 and PPSV23

In adults 60 years of age and older, immune responses to all 13 matched serotypes elicited by PREVNAR 20 were non-inferior to the immune responses to the same serotypes elicited by PREVNAR 13 in the evaluable immunogenicity population 1 month after vaccination (Table 9). Immune responses to 6 out of the 7 additional serotypes induced by PREVNAR 20 were non-inferior to the immune responses to these same serotypes induced by PPSV23 one month after vaccination. The response to serotype 8 missed the pre-specified statistical non-inferiority criterion of >0.5 GMR for the lower bound of the 95% CI with a GMR of 0.49.

It is however noted that the immune response to serotype 8 was within the range observed for the 13 serotypes in the PREVNAR 13 group. The GMFR in OPA titers for serotype 8 (GMFR of 22.1) was within the range observed for the 13 serotypes in the PREVNAR 13 group (GMFRs of 5.8 to 42.6). The same trend was also observed both in the percentage of participants with a ≥ 4 -fold rise in OPA titers: 77.8% for serotype 8 in the PREVNAR 20 group, within the range of 54.0% to 84.0% across the 13 serotypes in the PREVNAR 13 group, and the percentage of participants with OPA titers $\geq$ lower limit of quantitation (LLOQ) at 1 month after vaccination: 92.9% for serotype 8 in the PREVNAR 20 group, within the range of 76.0% to 96.6% across the 13 serotypes in the PREVNAR 13 group.

Table 9. OPA GMTs and GMRs 1 Month After Vaccination in Adults 60 Years of Age and Older Given PREVNAR 20 Compared to PREVNAR 13 for the 13 Matched Serotypes and PPSV23 for the 7 Additional Serotypes (Study 1007)^a

	PREVNAR 20	PREVNAR 13	PPSV23	Vaccine Comparison
	GMT ^b	GMT ^b	GMT ^b	GMR (95% CI) ^b
Serotype				
1	123	154		0.80 (0.71, 0.90)
3	41	48		0.85 (0.78, 0.93)
4	509	627		0.81 (0.71, 0.93)
5	92	110		0.83 (0.74, 0.94)
6A	889	1165		0.76 (0.66, 0.88)
6B	1115	1341		0.83 (0.73, 0.95)
7F	969	1129		0.86 (0.77, 0.96)
9V	1456	1568		0.93 (0.82, 1.05)
14	747	747		1.00 (0.89, 1.13)
18C	1253	1482		0.85 (0.74, 0.97)
19A	518	645		0.80 (0.71, 0.90)
19F	266	333		0.80 (0.70, 0.91)
23F	277	335		0.83 (0.70, 0.97)
Additional Serotypes				
8	466		848	0.55 (0.49, 0.62)
10A	2008		1080	1.86 (1.63, 2.12)
11A	4427		2535	1.75 (1.52, 2.01)
12F	2539		1717	1.48 (1.27, 1.72)
15B	2398		769	3.12 (2.62, 3.71)

Table 9. OPA GMTs and GMRs 1 Month After Vaccination in Adults 60 Years of Age and Older Given PREVNAR 20 Compared to PREVNAR 13 for the 13 Matched Serotypes and PPSV23 for the 7 Additional Serotypes (Study 1007)^a

	PREVNAR 20	PREVNAR 13	PPSV23	Vaccine Comparison
	GMT ^b	GMT ^b	GMT ^b	GMR (95% CI) ^b
22F	3666		1846	1.99 (1.70, 2.32)
33F	5126		3721	1.38 (1.21, 1.57)

Abbreviations: CI = confidence interval; GMR = geometric mean ratio; GMT = geometric mean OPA titer;

OPA = opsonophagocytic activity; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

a. Non-inferiority for a serotype was met if the lower bound of the 2-sided 95% CI for the GMT ratio (ratio of PREVNAR 20/comparator) was greater than 0.5 (2-fold criterion for non-inferiority).

b. GMTs and GMRs as well as the associated 2-sided CIs were based on the analysis of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination, and baseline OPA titers.

Immunogenicity in adults 18 through 59 years of age

PREVNAR 20 elicited immune responses to all 20 vaccine serotypes 1 month after vaccination in both of the younger age groups (Cohorts 2 and 3), and all were non-inferior to responses in adults 60 through 64 years of age (Table 10).

Table 10. Comparisons of OPA GMTs 1 Month After PREVNAR 20 in Adults 18 Through 49 or 50 Through 59 Years of Age to Adults 60 Through 64 Years of Age (Study 1007)^a

	18–49 Years	60–64 Years	18–49 Years / 60–64 Years	50–59 Years	60–64 Years	50–59 Years / 60–64 Years
	GMT ^b	GMT ^b	GMR (95% CI) ^b	GMT ^b	GMT ^b	GMR (95% CI) ^b
Serotype						
1	163	132	1.23 (1.01, 1.50)	136	132	1.03 (0.84, 1.26)
3	42	42	1.00 (0.87, 1.16)	43	41	1.06 (0.92, 1.22)
4	1967	594	3.31 (2.65, 4.13)	633	578	1.10 (0.87, 1.38)
5	108	97	1.11 (0.91, 1.36)	85	97	0.88 (0.72, 1.07)
6A	3931	1023	3.84 (3.06, 4.83)	1204	997	1.21 (0.95, 1.53)
6B	4260	1250	3.41 (2.73, 4.26)	1503	1199	1.25 (1.00, 1.56)
7F	1873	1187	1.58 (1.30, 1.91)	1047	1173	0.89 (0.74, 1.07)
9V	6041	1727	3.50 (2.83, 4.33)	1726	1688	1.02 (0.83, 1.26)
14	1848	773	2.39 (1.93, 2.96)	926	742	1.25 (1.01, 1.54)
18C	4460	1395	3.20 (2.53, 4.04)	1805	1355	1.33 (1.06, 1.68)
19A	1415	611	2.31 (1.91, 2.81)	618	600	1.03 (0.85, 1.25)
19F	655	301	2.17 (1.76, 2.68)	287	290	0.99 (0.80, 1.22)
23F	1559	325	4.80 (3.65, 6.32)	549	328	1.68 (1.27, 2.22)
Additional Serotypes						
8	867	508	1.71 (1.38, 2.12)	487	502	0.97 (0.78, 1.20)
10A	4157	2570	1.62 (1.31, 2.00)	2520	2437	1.03 (0.84, 1.28)
11A	7169	5420	1.32 (1.04, 1.68)	6417	5249	1.22 (0.96, 1.56)
12F	5875	3075	1.91 (1.51, 2.41)	3445	3105	1.11 (0.88, 1.39)
15B	4601	3019	1.52 (1.13, 2.05)	3356	2874	1.17 (0.88, 1.56)
22F	7568	4482	1.69 (1.30, 2.20)	3808	4228	0.90 (0.69, 1.17)
33F	7977	5693	1.40 (1.10, 1.79)	5571	5445	1.02 (0.81, 1.30)

- a. Non-inferiority for a serotype was met if the lower bound of the 2-sided 95% CI for the GMR (ratio of younger age group/60 through 64 years of age group) was greater than 0.5 (2-fold criterion for non-inferiority).
- b. GMTs, GMRs, and the associated 2-sided CIs were based on the analysis of log-transformed OPA titers using regression models with age group, sex, smoking status, and baseline OPA titers.

Study 1006

Immunogenicity of PREVNAR 20 in adults previously vaccinated with pneumococcal vaccine

PREVNAR 20 elicited immune responses to all 20 vaccine serotypes in adults 65 years of age and older with prior pneumococcal vaccination (Table 11).

Table 11. Pneumococcal OPA GMTs and GMFRs from Before to 1 Month After PREVNAR 20 in Adults 65 Years of Age and Older With Prior Pneumococcal Vaccination (Study 1006)

	Prior PPSV23			Prior PREVNAR 13			Prior PREVNAR 13 & PPSV23		
	GMT ^a		GMFR ^a (95% CI)	GMT ^a		GMFR ^a (95% CI)	GMT ^a		GMFR ^a (95% CI)
	Before	After		Before	After		Before	After	
Serotype									
1	24	51	2.2 (1.9, 2.5)	34	115	3.4 (2.9, 4.1)	41	82	2.0 (1.7, 2.4)
3	13	31	2.4 (2.1, 2.8)	15	54	3.5 (3.1, 4.1)	20	39	1.9 (1.6, 2.3)
4	30	146	4.9 (3.9, 6.1)	67	334	5.0 (4.1, 6.2)	78	191	2.4 (1.9, 3.1)
5	27	62	2.3 (2.0, 2.6)	38	87	2.3 (2.0, 2.6)	47	84	1.8 (1.5, 2.0)
6A	58	731	12.6 (9.5, 16.7)	127	1051	8.3 (6.6, 10.4)	161	1048	6.5 (4.7, 9.1)
6B	109	720	6.6 (5.2, 8.4)	176	1179	6.7 (5.4, 8.3)	259	1030	4.0 (3.0, 5.2)
7F	161	367	2.3 (1.9, 2.7)	210	545	2.6 (2.2, 3.0)	205	337	1.6 (1.4, 2.0)
9V	206	503	2.4 (2.1, 2.9)	347	1058	3.1 (2.6, 3.6)	345	721	2.1 (1.7, 2.6)
14	213	386	1.8 (1.5, 2.1)	286	660	2.3 (1.9, 2.8)	342	581	1.7 (1.4, 2.1)
18C	175	552	3.2 (2.5, 3.9)	217	846	3.9 (3.2, 4.8)	273	611	2.2 (1.8, 2.7)
19A	84	241	2.9 (2.4, 3.4)	124	356	2.9 (2.4, 3.4)	184	345	1.9 (1.6, 2.2)
19F	61	160	2.6 (2.2, 3.1)	89	242	2.7 (2.3, 3.2)	118	218	1.9 (1.5, 2.3)
23F	23	151	6.6 (5.1, 8.5)	48	447	9.3 (7.4, 11.8)	64	288	4.5 (3.4, 6.0)
Additional Serotypes									
8	58	207	3.6 (2.9, 4.4)	27	609	22.5 (17.2, 29.4)	137	292	2.1 (1.6, 2.8)
10A	212	956	4.5 (3.5, 5.7)	134	1923	14.4 (10.9, 19.0)	360	1595	4.4 (3.3, 6.0)
11A	532	1348	2.5 (2.0, 3.2)	270	1807	6.7 (5.0, 9.0)	491	1514	3.1 (2.2, 4.4)
12F	139	1000	7.2 (5.5, 9.5)	53	1684	31.7 (23.1, 43.4)	358	1367	3.8 (2.7, 5.5)
15B	145	625	4.3 (3.3, 5.7)	74	1402	18.9 (13.0, 27.4)	199	956	4.8 (3.1, 7.5)
22F	161	1779	11.1 (8.0, 15.3)	61	4099	66.9 (46.5, 96.4)	266	2616	9.8 (6.2, 15.6)
33F	1137	2059	1.8 (1.5, 2.2)	564	3041	5.4 (4.2, 6.8)	1269	2234	1.8 (1.4, 2.2)

Abbreviations: GMT = geometric mean OPA titer; GMFR = geometric mean fold rise

- a. GMTs, GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers or fold rises and the corresponding CIs based on the Student t distribution. GMTs and GMFRs were calculated from those with valid OPA titers at both before and 1 month after vaccination timepoints.

14.2.2. Clinical Trials in Infants, Children and Adolescents 6 Weeks Through 17 Years of Age

Infants and Toddlers (6 Weeks Through 15 months of Age) Receiving a Routine Vaccination Schedule

Immune Responses Following a 3-Dose Vaccination Series (Study 1012)

3-Dose Series (2-Dose Primary Series Followed by a Toddler Dose)

One month after the 2 infant doses, the observed IgG GMCs for 9 of the 13 matched serotypes were non-inferior (NI) to those in the PREVNAR 13 group, and serotypes 6A, 6B, 9V, and 23F did not meet the 2-fold statistical criterion for noninferiority. The immune responses to the additional 7 serotypes after PREVNAR 20 were non-inferior to the lowest IgG GMC among the 13 serotypes (serotype 6B) in PREVNAR 13. The percentages of participants with predefined serotype-specific IgG concentrations 1 month after Dose 2 of PREVNAR 20 for 4 of the 13 matched serotypes were non-inferior to those of the PREVNAR 13 group based on a 10% non-inferiority criteria; and serotypes 1, 3, 4, 5, 6A, 6B, 9V, 18C and 23F did not meet the statistical criterion for noninferiority. For the 7 additional serotypes, the percentages of participants with predefined serotype-specific IgG concentrations 1 month after Dose 2 of PREVNAR 20 for 5 of the 7 additional serotypes were non-inferior to the serotype with the lowest percentage among the 13 serotypes (serotype 6B) in the PREVNAR 13 group and serotypes 10A and 12F did not meet the statistical noninferiority criterion. The clinical relevance of these findings after Dose 2 is unknown. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the PREVNAR 13 group after two infant doses.

One month after the third (toddler) dose, the observed IgG GMCs of PREVNAR 20 were non-inferior to the PREVNAR 13 group for 12 of 13 matched serotypes except for serotype 6B and all 7 additional serotypes were non-inferior to the lowest IgG GMC in the PREVNAR 13 group. Additionally, the IgG GMCs for the 7 additional serotypes were higher compared with the IgG GMCs from the corresponding serotypes in the PREVNAR 13 group after the toddler dose.

Functional responses, as measured by OPA GMTs, for the 13 matched serotypes at 1 month after the second infant dose and 1 month after the toddler dose in the PREVNAR 20 group were generally similar to the observed OPA GMTs in the PREVNAR 13 group for most serotypes and the observed OPA GMTs were substantially higher for the 7 additional serotypes at both timepoints in the PREVNAR 20 group than in the PREVNAR 13 group. Increases in IgG and OPA antibody responses after PREVNAR 20 following Dose 2 to after Dose 3 were observed for all 20 serotypes including those that missed noninferiority, indicative of immunological memory. Evidence of functional responses, memory responses generated with infant doses (boosting of IgG and OPA responses after the toddler dose), and generally similar distributions of IgG concentrations and OPA titres in PREVNAR 20 and PREVNAR 13 groups support the immunogenicity of PREVNAR 20 in a 3-dose series for all serotypes including those that missed noninferiority.

Immune Responses Following a 4-Dose Vaccination Series (Study 1011)

4-Dose Series (3-Dose Primary Series Followed by a Toddler Dose)

Noninferiority of the percentages of participants with predefined serotype-specific IgG concentrations one month after Dose 3 was met for 8 of the 13 serotypes based on a 10% noninferiority criteria and five of the 13 matched serotypes (serotypes 1, 3, 4, 9V and 23F) did not meet the pre-specified noninferiority criteria, as the lower bounds of the 2-sided 95% CIs for the difference in percentages (PREVNAR 20 minus PREVNAR 13) were below -10%. Six of the 7 additional serotypes met the noninferiority criterion; serotype 12F missed the statistical noninferiority criterion. The IgG GMC for PREVNAR 20 were noninferior for all 13 matched serotypes to PREVNAR 13 one month after Dose 3 based on a 2-fold noninferiority criterion (0.5). The IgG GMCs for all 7 additional serotypes were noninferior to the lowest IgG GMC among PREVNAR 13 serotypes. Results are shown in Table 12.

Table 12. Percentage of Participants With Predefined Pneumococcal IgG Concentrations and Pneumococcal IgG GMCs (mcg/mL) One Month After Dose 3 of a 4-Dose Series (Study 1011)^a

	Percentages of Participants With Predefined IgG Concentrations ^b			IgG GMCs		
	PREVNAR 20 N ^c = 831-833	PREVNAR 13 N ^c = 801-802	PREVNAR 20 – PREVNAR 13	PREVNAR 20 N ^c = 831-833	PREVNAR 13 N ^c = 801-802	PREVNAR 20/ PREVNAR 13
	%	%	% (95% CI ^d)	GMC ^e	GMC ^e	GMR (95% CI ^e)
Serotypes						
1	79.8	88.4	-8.6 (-12.1, -5.1)	0.74	1.14	0.65 (0.59, 0.72)
3	52.1	67.6	-15.5 (-20.1, -10.8)	0.36	0.51	0.70 (0.64, 0.76)
4	79.7	88.2	-8.4 (-12.0, -4.9)	0.75	1.08	0.70 (0.63, 0.78)
5	82.5	86.8	-4.3 (-7.8, -0.8)	0.66	0.96	0.69 (0.61, 0.77)
6A	93.5	95.9	-2.4 (-4.6, -0.2)	1.95	2.69	0.72 (0.65, 0.81)
6B	88.3	92.4	-4.1 (-7.0, -1.2)	0.61	1.02	0.60 (0.51, 0.70)
7F	96.6	97.6	-1.0 (-2.7, 0.7)	1.71	2.29	0.75 (0.69, 0.81)
9V	81.9	89.8	-7.9 (-11.3, -4.6)	0.87	1.21	0.72 (0.65, 0.80)
14	93.4	94.1	-0.8 (-3.1, 1.6)	2.16	2.72	0.79 (0.71, 0.89)
18C	92.6	93.1	-0.6 (-3.1, 1.9)	1.31	1.71	0.77 (0.70, 0.84)
19A	97.1	98.1	-1.0 (-2.6, 0.5)	0.72	0.91	0.79 (0.72, 0.86)
19F	96.9	96.6	0.2 (-1.5, 2.0)	1.59	2.00	0.79 (0.73, 0.86)
23F	77.9	85.5	-7.6 (-11.4, -3.9)	0.82	1.25	0.66 (0.58, 0.75)
Additional Serotypes^f						
8	96.8	f	11.2 (8.6, 14.0)	1.80	f	1.98 (1.81, 2.16)
10A	82.2	f	-3.3 (-6.9, 0.3)	1.21	f	1.32 (1.18, 1.49)
11A	92.7	f	7.1 (4.2, 10.2)	1.39	f	1.52 (1.39, 1.67)
12F	67.5	f	-18.1 (-22.1, -14.0)	0.55	f	0.60 (0.54, 0.67)
15B	98.2	f	12.7 (10.2, 15.4)	4.40	f	4.82 (4.39, 5.30)
22F	98.3	f	12.8 (10.3, 15.5)	3.71	f	4.06 (3.68, 4.48)
33F	86.7	f	1.1 (-2.2, 4.5)	1.49	f	1.64 (1.46, 1.83)

Abbreviations: CI = confidence interval; GMC = geometric mean concentration; GMR = geometric mean ratio; IgG = immunoglobulin G; LLOQ = lower limit of quantitation.

Note: Noninferiority for a serotype was concluded if the lower bound of the 2-sided 95% CI for the percentage difference (PREVNAR 20 – PREVNAR 13) was > -10% or the lower bound of the 2-sided 95% CI for the GMR (PREVNAR 20 to PREVNAR 13) was >0.5 for that serotype.

Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

- Study 1011 was conducted in the United States and the territory of Puerto Rico (NCT04382326).
- The predefined IgG concentration was ≥0.35 mcg/mL for all serotypes except for serotypes 5, 6B and 19A which were ≥0.23 mcg/mL, ≥0.10 mcg/mL and ≥0.12 mcg/mL respectively.
- N = Number of participants with valid IgG concentrations.
- Two-sided CI based on the Miettinen and Nurminen method.
- GMCs, GMRs and the associated 2-sided CIs were calculated by exponentiating the means and the mean differences (PREVNAR 20 – PREVNAR 13) of the logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution).
- For the GMRs and the percentage differences of the 7 additional serotypes, the IgG results from serotype 19A and 23F (vaccine serotype with the lowest GMC and percentage, excluding serotype 3) in the PREVNAR 13 group was used in the comparisons the IgG GMCs to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the PREVNAR 13 group were 1.6%, 1.2%, 1.5%, 0.1%, 2.6%, 0.9% and 1.1%, respectively.

The percentage of participants with predefined pneumococcal IgG concentrations and pneumococcal IgG GMCs one month after dose 4 of a 4-dose primary infant series are presented in Table 13. The IgG GMCs for PREVNAR 20 were noninferior for all 13 matched serotypes to PREVNAR 13 one month after Dose 4 (toddler dose) based on a 2-fold noninferiority criterion. The IgG GMCs for all 7 additional serotypes were noninferior to the lowest IgG GMC among PREVNAR 13 serotypes (other than serotype 3) based on a 2-fold noninferiority criterion. This was also the case for the IgG GMCs for PREVNAR 20, 1 month after Dose 3.

Table 13. Percentage of Participants With Predefined Pneumococcal IgG Concentrations and Pneumococcal IgG GMCs (mcg/mL) One Month After Dose 4 of a 4-Dose Series (Study 1011)^a

	Percentages of Participants With Predefined IgG Concentrations ^b			IgG GMCs		
	PREVNAR 20 N ^c = 753-755	PREVNAR 13 N ^c = 744-745	PREVNAR 20 – PREVNAR 13	PREVNAR 20 N ^c = 753-755	PREVNAR 13 N ^c = 744-745	PREVNAR 20/ PREVNAR 13
	%	%	% (95% CI ^d)	GMC ^e	GMC ^e	GMR (95% CI ^e)
Serotypes						
1	94.3	97.2	-2.9 (-5.0, -0.8)	1.47	2.12	0.69 (0.63, 0.76)
3	73.6	85.8	-12.1 (-16.2, -8.1)	0.56	0.85	0.66 (0.61, 0.73)
4	98.9	99.1	-0.1 (-1.3, 1.0)	3.77	4.84	0.78 (0.70, 0.86)
5	97.9	97.7	0.2 (-1.4, 1.7)	1.87	2.51	0.74 (0.67, 0.82)
6A	99.5	99.7	-0.3 (-1.1, 0.5)	9.01	11.69	0.77 (0.70, 0.85)
6B	99.1	99.5	-0.4 (-1.4, 0.6)	4.01	5.74	0.70 (0.62, 0.79)
7F	99.5	99.9	-0.4 (-1.2, 0.3)	3.91	5.18	0.76 (0.70, 0.82)
9V	98.5	98.9	-0.4 (-1.6, 0.8)	3.44	4.30	0.80 (0.73, 0.88)
14	98.9	99.5	-0.5 (-1.6, 0.4)	5.68	6.34	0.90 (0.81, 1.00)
18C	98.9	98.7	0.3 (-0.9, 1.5)	3.46	4.69	0.74 (0.67, 0.82)
19A	99.9	99.7	0.1(-0.5, 0.9)	3.53	4.13	0.85 (0.77, 0.94)
19F	98.8	98.9	-0.1 (-1.3, 1.1)	5.01	5.79	0.86 (0.78, 0.96)
23F	97.2	98.1	-0.9 (-2.5, 0.7)	3.95	6.18	0.64 (0.57, 0.72)
Additional Serotypes^f						
8	99.5	f	2.3 (1.1, 3.8)	3.97	f	1.87 (1.71, 2.06)
10A	97.7	f	0.6 (-1.1, 2.3)	6.22	f	2.94 (2.64, 3.26)
11A	98.8	f	1.6 (0.2, 3.2)	3.53	f	1.67 (1.51, 1.84)
12F	95.2	f	-1.9 (-4.0, 0.0)	1.85	f	0.88 (0.79, 0.97)
15B	99.7	f	2.6 (1.4, 4.0)	12.59	f	5.95 (5.39, 6.55)
22F	99.6	f	2.4 (1.3, 3.9)	10.60	f	5.01 (4.54, 5.52)
33F	99.5	f	2.3 (1.1, 3.8)	9.31	f	4.40 (3.99, 4.85)

Abbreviations: CI = confidence interval; GMC = geometric mean concentration; GMR = geometric mean ratio; IgG = immunoglobulin G; LLOQ = lower limit of quantitation.

Note: Noninferiority for a serotype was concluded if the lower bound of the 2-sided 95% CI for the GMR (PREVNAR 20 to PREVNAR 13) was >0.5 for that serotype.

Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

- Study 1011 was conducted in the United States and the territory of Puerto Rico (NCT04382326).
- The predefined IgG concentration was ≥0.35 mcg/mL for all serotypes except for serotypes 5, 6B and 19A which were ≥0.23 mcg/mL, ≥0.10 mcg/mL and ≥0.12 mcg/mL respectively.
- N = Number of participants with valid IgG concentrations.
- Two-sided CI based on the Miettinen and Nurminen method.

Table 13. Percentage of Participants With Predefined Pneumococcal IgG Concentrations and Pneumococcal IgG GMCs (mcg/mL) One Month After Dose 4 of a 4-Dose Series (Study 1011)^a

	Percentages of Participants With Predefined IgG Concentrations ^b			IgG GMCs		
	PREVNAR 20 N ^c = 753-755	PREVNAR 13 N ^c = 744-745	PREVNAR 20 – PREVNAR 13	PREVNAR 20 N ^c = 753-755	PREVNAR 13 N ^c = 744-745	PREVNAR 20/ PREVNAR 13
	%	%	% (95% CI ^d)	GMC ^e	GMC ^e	GMR (95% CI ^e)

- e. GMCs, GMRs and the associated 2-sided CIs were calculated by exponentiating the means and the mean differences (PREVNAR 20 – PREVNAR 13) of the logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution).
- f. For the GMRs and the percentage differences of the 7 additional serotypes, the IgG results from serotype 1 (vaccine serotype with the lowest GMC and percentage excluding serotype 3) in the 13vPnC group was used in the comparisons, the IgG GMCs to serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F in the PREVNAR 13 group were 0.03 µg/mL, 0.01 µg/mL, 0.02 µg/mL, 0.01 µg/mL, 0.02 µg/mL, 0.00 µg/mL and 0.01 µg/mL, respectively.

Additional Important Measures of Immune Response

OPA responses after 3 and 4 doses of PREVNAR 20

Serotype-specific OPA GMTs at 1 month after Dose 3 and 1 month after Dose 4 were descriptively evaluated in a subset of participants who had received PREVNAR 20 and PREVNAR 13 in Study 8 (Table 14). The OPA GMTs for the 13 matched serotypes 1 month after Dose 3 and 1 month after Dose 4 in the PREVNAR 20 group were generally similar to the OPA GMTs in the PREVNAR 13 group for most serotypes, and the observed OPA GMTs were substantially higher for the 7 additional serotypes at both timepoints in the PREVNAR 20 group than in the PREVNAR 13 group.

PREVNAR 20 elicits OPA immune responses that are comparable to PREVNAR 13 for the 13 matched serotypes and the 7 additional serotypes after 3 doses in infants and Dose 4 in toddlers. PREVNAR 20 also elicits functional antibody to all 20 serotypes that was observed 1 month after Dose 3 and 1 month after Dose 4. PREVNAR 20 immune responses also show boosting after Dose 4, indicating that a memory response was elicited by the 3 infant doses.

Table 14. Pneumococcal OPA GMTs One Month After Dose 3 and Dose 4 of a 4-Dose Series (Study 1011)^a

	PREVNAR 20 N ^b = 85-105 After Dose 3	PREVNAR 13 N ^b = 84-113 After Dose 3	PREVNAR 20 N ^b = 80-99 After Dose 4	PREVNAR 13 N ^b = 77-103 After Dose 4
	GMT ^c (95% CI ^c)	GMT ^c (95% CI ^c)	GMT ^c (95% CI ^c)	GMT ^c (95% CI ^c)
Serotypes				
1	26 (21, 33)	34 (27, 42)	36 (27, 48)	66 (50, 87)
3	51 (43, 61)	63 (53, 76)	62 (49, 78)	102 (86, 120)
4	339 (252, 455)	280 (207, 378)	621 (435, 887)	961 (714, 1294)
5	32 (27, 39)	39 (32, 47)	55 (45, 67)	69 (54, 87)
6A	910 (763, 1084)	936 (757, 1156)	1384 (1092, 1753)	1767 (1329, 2348)
6B	318 (242, 419)	516 (409, 651)	666 (489, 906)	1211 (861, 1703)
7F	1222 (1020, 1465)	1149 (926, 1424)	2022 (1673, 2444)	2099 (1741, 2531)
9V	661 (482, 906)	594 (421, 838)	2609 (1913, 3558)	3210 (2500, 4123)

Table 14. Pneumococcal OPA GMTs One Month After Dose 3 and Dose 4 of a 4-Dose Series (Study 1011)^a

	PREVNAR 20 N^b = 85-105 After Dose 3	PREVNAR 13 N^b = 84-113 After Dose 3	PREVNAR 20 N^b = 80-99 After Dose 4	PREVNAR 13 N^b = 77-103 After Dose 4
	GMT^c (95% CI^c)	GMT^c (95% CI^c)	GMT^c (95% CI^c)	GMT^c (95% CI^c)
14	415 (323, 535)	420 (330, 535)	667 (523, 850)	593 (462, 761)
18C	1153 (910, 1460)	996 (754, 1317)	1973 (1472, 2643)	2425 (1914, 3072)
19A	108 (78, 149)	109 (79, 151)	844 (622, 1145)	1357 (1007, 1829)
19F	84 (67, 105)	116 (90, 149)	246 (179, 337)	373 (272, 513)
23F	255 (186, 350)	295 (215, 406)	827 (554, 1235)	1532 (1118, 2100)
Additional Serotypes				
8	665 (503, 880)	18 (17, 20)	1228 (901, 1673)	26 (21, 31)
10A	2558 (1869, 3501)	37 (33, 42)	3674 (2746, 4916)	57 (44, 74)
11A	289 (212, 395)	50 (46, 55)	2728 (1975, 3768)	69 (53, 89)
12F	7677 (5952, 9901)	28 (24, 33)	9320 (7037, 12343)	31 (26, 37)
15B	1560 (1090, 2233)	18 (16, 22)	3035 (2138, 4308)	23 (17, 30)
22F	6797 (5170, 8936)	9 (9, 9)	11077 (7956, 15422)	15 (11, 20)
33F	7388 (4803, 11365)	198 (177, 220)	19216 (13193, 27990)	363 (292, 451)

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; OPA = opsonophagocytic activity.

Note: Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

Note: OPA titers were determined on serum from randomly selected subsets of participants assuring equal representation of both vaccine groups.

- Study 1011 was conducted in the United States and the territory of Puerto Rico (NCT04382326).
- N = Number of participants with valid OPA titers.
- GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student's t distribution).

Boosting responses after the last dose in a 4-dose infant vaccination series

PREVNAR 20 shows boosting of IgG and OPA responses after Dose 4, indicating that a memory response was elicited by the 3 infant doses (see Tables 12, 13, and 14).

In summary, PREVNAR 20 elicits immune responses that are comparable to PREVNAR 13 for the 13 matched serotypes and the 7 additional serotypes after 3 doses in infants and a fourth dose in toddlers. PREVNAR 20 also elicits functional antibody and booster responses to all 20 serotypes from 1 month after Dose 3 and 1 month after Dose 4. Thus, the totality of data show that a 4-dose series of PREVNAR 20 elicited immune responses expected to provide children protection against pneumococcal disease similar to that of PREVNAR 13 for all 20 vaccine serotypes.

Children 15 Months Through 17 Years of Age (Study 1014)

In a multicenter, single-arm trial (Study 1014), participants were enrolled into the study by age group (approximately 200 participants per group) to receive a single dose of PREVNAR 20 as described below.

Children 15 months to less than 24 months of age previously vaccinated with PREVNAR 13

In the 15 to less than 24 months age group, participants had been previously vaccinated with 3 or 4 doses of PREVNAR 13. Increases in IgG concentrations from before to 1 month after PREVNAR 20 were observed for all 20 vaccine serotypes. The observed IgG GMFRs to the 7 additional serotypes ranged

from 27.9 to 1847.7. For 6 of the 7 additional serotypes, 83.2% – 100.0% had predefined IgG concentrations, and 40% for serotype 12F. All participants achieved OPA titres $\geq$ LLOQ for serotype 12F 1 month after PREVNAR 20.

Children 24 months to less than 5 years of age previously vaccinated with PREVNAR 13

In the 24 months to less than 5 years age group, participants had been previously vaccinated with 3 or 4 doses of PREVNAR 13. Increases in IgG concentrations from before to 1 month after PREVNAR 20 were observed for all 20 vaccine serotypes. The observed IgG GMFRs to the 7 additional serotypes ranged from 36.6 to 796.2. For the 7 additional serotypes, 71.2% - 94.6% had $\geq$ 4-fold rise in OPA titres.

Children 5 years to less than 18 years of age previously unvaccinated or vaccinated with PREVNAR 13

In the 5 to less than 10 years and 10 to less than 18 years age groups, participants could be unvaccinated or previously vaccinated with PREVNAR 13. PREVNAR 20 elicited robust IgG and OPA immune responses to the 20 vaccine serotypes after a single dose in participants 5 to less than 18 years of age. OPA GMFRs ranged from 11.5 to 499.0 to the 7 additional serotypes and increases in OPA GMTs were observed for all 20 vaccine serotypes.

Preterm infants

The safety and tolerability of PREVNAR 20 were evaluated in Study 1013, which included 111 late preterm infants (>34 to <37 weeks gestational age) among the total study population. Participants were randomized to receive a 4-dose series of either PREVNAR 20 (N=77) or PREVNAR 13 (N=34). Studies have not been specifically conducted to describe the immunogenicity of PREVNAR 20 in preterm infants. Based on experience with PREVNAR and PREVNAR 13, immune responses are elicited in preterm infants, although they may be lower than in term infants.

14.2.3. Concomitant Vaccine Administration

Infants and Children

In Study 1012, the concomitant administration of Infanrix hexa (containing DTaP, HBV, IPV, and Hib antigens) with all 3 doses of PREVNAR 20 or PREVNAR 13 and single doses of M-M-RVAXPRO and Varilrix vaccine (containing MMR and varicella antigens, respectively) were also administered with the third dose and evaluated 1 month after the third (toddler) dose of PREVNAR 20 or PREVNAR 13. Noninferiority was demonstrated for immune responses to diphtheria, tetanus, acellular pertussis, hepatitis B, poliovirus, Hib, MMR, and varicella vaccine antigens co-administered with PREVNAR 20 compared with PREVNAR 13. The results from Study 1012 support co-administration of PREVNAR 20 with routine pediatric vaccines. No safety concerns were identified in this study.

In Study 1011, the concomitant administration of Pediarix (containing DTaP, HBV, IPV antigens) and Hiberix (Hib antigen) with each of the 3 infant doses of either PREVNAR 20 or PREVNAR 13 were evaluated 1 month after the third dose. Concomitant administration of single doses of M-M-R II (MMR antigens) and VARIVAX (varicella antigens) with the fourth dose of either PREVNAR 20 or PREVNAR 13 were evaluated 1 month following vaccination. Noninferiority was demonstrated for immune responses to the co-administered diphtheria, tetanus, acellular pertussis, hepatitis B virus, poliovirus, and Hib vaccine antigens 1 month after 3 infant doses and coadministered MMR, and varicella virus vaccine antigens after the fourth (toddler) dose of PREVNAR 20 compared with PREVNAR 13. The results from

Study 1011 support co-administration of PREVNAR 20 with routine pediatric vaccines. No safety concerns were identified in this study.

Influenza and rotavirus vaccines were permitted to be administered concomitantly at any time during these studies according to local or national recommendations.

Adults

Clinical trial in adults to assess PREVNAR 20 given with influenza vaccine, adjuvanted quadrivalent, (QIV)

In a double-blind, randomized study (Study 1004), adults 65 years of age and older were randomized with or without a history of pneumococcal vaccination in a 1:1 ratio to receive PREVNAR 20 concomitantly administered with an influenza vaccine, adjuvanted (Fluad Quadrivalent [QIV]; Group 1, N = 898) or PREVNAR 20 administered 1 month after receiving QIV (Group 2, N = 898). Pneumococcal serotype-specific OPA GMTs were evaluated 1 month after PREVNAR 20 and influenza vaccine strain hemagglutinin inhibition assay (HAI) GMTs were evaluated 1 month after QIV. The non-inferiority criteria for the comparisons of OPA GMTs (lower limit of the 2-sided 95% CI of the GMT ratio [Group 1/Group 2] >0.5, 2-fold non-inferiority criterion) were met for all 20 pneumococcal serotypes in PREVNAR 20. The non-inferiority criteria for the comparisons of HAI GMTs (lower limit of the 2-sided 95% CI for the GMT ratio [Group 1/Group 2] >0.67, 1.5-fold non-inferiority criterion) were also met for all 4 influenza vaccine strains.

Clinical trial in adults to assess PREVNAR 20 given with a third (booster) dose of COVID-19 mRNA vaccine

In a double-blind, randomized descriptive study (Study 1026), adults 65 years of age and older who had received 2 doses of COVID-19 mRNA vaccine at least 6 months earlier were randomized in a 1:1:1 ratio to receive PREVNAR 20 concomitantly administered with a third (booster) dose of COVID-19 mRNA vaccine (N = 190), PREVNAR 20 administered alone (N = 191), or a third (booster) dose of COVID-19 mRNA vaccine administered alone (N = 189).

Immune responses to both vaccines were observed after co-administration of PREVNAR 20 and COVID-19 mRNA vaccine. OPA GMTs for the 20 pneumococcal serotypes were similar to PREVNAR 20 administered alone and IgG GMCs for the full-length S-binding protein were similar to COVID-19 mRNA vaccine administered alone.

14.3. Clinical Studies of PREVNAR 13

The efficacy and effectiveness of PREVNAR 13 against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F is relevant to PREVNAR 20, since the vaccines are manufactured similarly and contain 13 of the same polysaccharide conjugates.

PREVNAR 13 CAPiTA Efficacy Study

The efficacy of PREVNAR 13 against vaccine-type (VT) pneumococcal community acquired pneumonia (CAP) and IPD was assessed in a randomized, double-blind, placebo-controlled study (Community-Acquired Pneumonia Immunization Trial in Adults [CAPiTA]) conducted over four years in the Netherlands. A total of 84,496 participants 65 years of age and older received a single dose of either PREVNAR 13 or placebo in a 1:1 randomization; 42,240 participants were vaccinated with PREVNAR 13 and 42,256 participants were vaccinated with placebo. Chronic medical conditions (asthma, diabetes, heart, liver, and/or lung diseases) were reported in 42.3% of study participants at baseline.

The primary endpoint was the prevention of a first episode of confirmed VT-CAP (defined as the presence of ≥2 pre-specified clinical criteria, chest X-ray consistent with CAP, and positive VT-specific

Urinary Antigen Detection assay or isolation of VT *S. pneumoniae* from blood or other sterile site). The secondary endpoints were the prevention of a first episode of 1) confirmed non-bacteremic/non-invasive (NB/NI) VT-CAP (an episode of VT-CAP for which the blood or sterile site cultures were negative for *S. pneumoniae*) and 2) VT-IPD (the presence of *S. pneumoniae* in a sterile site).

The per-protocol population was the primary population for analysis of all primary and secondary efficacy objectives. The mean duration of follow-up was 3.97 years. PREVNAR 13 demonstrated statistically significant vaccine efficacy (VE) in preventing first episodes of VT pneumococcal CAP, NB/NI VT pneumococcal CAP, and VT-IPD (Table 15).

Table 15. Vaccine Efficacy for the Primary and Secondary Endpoints of the CAPiTA Study

Efficacy endpoints	Total Number of Episodes	PREVNAR 13 N=42,240	Placebo N=42,256	VE (%)	95.2% CI	p value
		n	n			
VT pneumococcal CAP	139	49	90	45.6	21.8, 62.5	0.0006
NB/NI VT pneumococcal CAP	93	33	60	45	14.2, 65.3	0.0067
VT-IPD	35	7	28	75	41.1, 90.9	0.0005

Abbreviations: CAP = community-acquired pneumonia; N = number of participants; NB/NI = non-bacteremic/non-invasive; IPD = invasive pneumococcal disease; VE = vaccine efficacy; VT = vaccine-type.

PREVNAR 13 Effectiveness Against Acute Otitis Media

Effectiveness of PREVNAR 13 against acute otitis media (AOM) due to the six additional *S. pneumoniae* serotypes included in PREVNAR 13 (i.e., 1, 3, 5, 6A, 7F, and 19A) has been observed in a prospectively designed, single-centre, non-randomized pediatric surveillance study in the US (4-dose schedule).

PREVNAR 13 Immune Responses in Special Populations

Sickle cell disease

An open-label, single-arm study with 2 doses of PREVNAR 13 given 6 months apart was conducted in 158 children and adolescents 6 to <18 years of age with sickle cell disease who were previously vaccinated with 1 or more doses of PPSV23 at least 6 months prior to enrollment. After the first vaccination, PREVNAR 13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were higher when compared to levels prior to vaccination. After the second dose, IgG GMCs and OPA GMTs were generally comparable to those after the first dose. One year after the second dose, antibody levels measured by both IgG GMCs and OPA GMTs were higher than levels prior to the first dose of PREVNAR 13, except the IgG GMCs for serotypes 3 and 5 that were numerically similar. The clinical benefit of the second dose remains uncertain (de Montalembert *et al.* 2015, *Pediatr Blood Cancer*).

HIV infection

In HIV-infected children and adults free of active acquired immunodeficiency syndrome-related illness, and not previously vaccinated with a pneumococcal vaccine, 151 participants 6 to <18 years of age and 152 participants 18 years of age and older received three doses of PREVNAR 13 and subsequently a single dose of PPSV23. Vaccines were administered at 1 month intervals. Immune responses were assessed in 128 to 133 evaluable participants 6 to <18 years of age and in 131 to 137 evaluable participants 18 years of age and older approximately 1 month after each dose of vaccine. Immune responses approximately 1 month after each dose of vaccine elicited antibody levels, measured by both immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs), that were statistically significantly higher compared to levels prior to

vaccination. After the second and third dose of PREVNAR 13, immune responses were similar to or higher than those after the first dose (Bhorat *et al.* 2015, AIDS 29:1345).

In HIV-infected adults free of active AIDS-related illness and previously vaccinated with PPSV23 administered at least 6 months prior to enrollment, 329 participants received three doses of PREVNAR 13: at enrollment, 6 and 12 months after the first dose. After the first vaccination, PREVNAR 13 elicited antibody levels measured by both IgG GMCs and OPA GMTs that were higher compared to levels prior to vaccination. After the second and third dose of PREVNAR 13, immune responses were comparable to or higher than those after the first dose. Subjects who received 2 or more previous doses of PPSV23 showed a similar immune response compared with subjects who received a single previous dose (Glesby *et al.* 2015, JID 212:18).

Hematopoietic stem cell transplant (HSCT)

In children and adults with an allogeneic HSCT at ≥ 2 years of age and with complete hematologic remission of underlying disease (or very good partial remission in the case of lymphoma and myeloma), 61 participants 2 to <18 years of age and 190 participants 18 years of age and older received three doses of PREVNAR 13 at intervals of at least 1 month between doses. The first dose was administered at 3 to 6 months after HSCT. A fourth booster dose of PREVNAR 13 was administered 6 months after the third dose, followed by a single dose of PPSV23 at 1 month after the fourth dose. Immune responses as measured by IgG GMCs were assessed in 41 to 52 evaluable participants 2 to <18 years of age and in 127 to 159 evaluable participants 18 years of age and older approximately 1 month after vaccination. PREVNAR 13 elicited increased antibody levels after each dose of PREVNAR 13. Approximately 1 month after vaccination, immune responses after the fourth dose of PREVNAR 13 were significantly increased for all serotypes compared with the third dose, with the exception of serotype 3 in the 2 to <18 years age group. Overall, participants 2 to <18 years of age had generally higher serotype-specific immune responses as compared to those 18 years of age and older (Cordonnier *et al.* 2015, CID 61:313).

16. Non-Clinical Toxicology

General Toxicology:

Non-clinical data revealed no special hazard for humans based on conventional studies of repeated dose toxicity.

Carcinogenicity:

Carcinogenic potential was not assessed, as carcinogenicity studies were not considered relevant to this vaccine.

Genotoxicity:

Genotoxic potential was not assessed, as genotoxicity studies were not considered relevant to this vaccine.

Reproductive and Developmental Toxicology:

In a fertility and developmental toxicity study, female rabbits were administered PREVNAR 20 by intramuscular injection twice prior to mating (17 days and 4 days prior to mating) and twice during gestation (Gestation Days 10 and 24), 0.5 mL/rabbit/occasion (a single human dose). No adverse effects

on pre-weaning development were observed. There were no vaccine-related fetal malformations or variations.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PREVNAR 20™

Pneumococcal 20-valent Conjugate Vaccine (Diphtheria CRM₁₉₇ Protein)

Suspension for Intramuscular Injection

This Patient Medication Information is written for the person who will be taking **PREVNAR 20**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **PREVNAR 20**, talk to a healthcare professional.

What PREVNAR 20 is used for:

PREVNAR 20 is a pneumococcal vaccine given to:

- Children from 6 weeks through 17 years of age (prior to the 18th birthday) to prevent invasive pneumococcal diseases such as bacteremic pneumonia (lung infection with bacteria in the blood stream), sepsis or bacteremia (bacteria in the blood stream) and meningitis (inflammation around the brain), caused by 20 types of the bacteria *Streptococcus pneumoniae*.
- Adults 18 years of age and older to prevent pneumococcal diseases such as: pneumonia (lung infection), bacteremic pneumonia (lung infection with bacteria in the blood stream), sepsis or bacteremia (bacteria in the blood stream) and meningitis (inflammation around the brain), caused by 20 types of the bacteria *Streptococcus pneumoniae*.

These illnesses are more likely to occur in individuals with certain diseases or behaviours, such as smoking.

How PREVNAR 20 works:

This vaccine works by helping the body to make its own antibodies, which protect against these diseases. PREVNAR 20 provides protection against 20 types of *Streptococcus pneumoniae* bacteria.

The ingredients in PREVNAR 20 are:

Medicinal ingredients: One dose (0.5 mL) contains the following active substances linked to the non-toxic diphtheria (CRM₁₉₇) carrier protein:

- 2.2 micrograms of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F
- 4.4 micrograms of polysaccharide for serotype 6B

Non-medicinal ingredients: aluminum phosphate, polysorbate 80, sodium chloride, succinic acid, water for injection.

PREVNAR 20 comes in the following dosage form(s):

A white suspension for intramuscular injection, provided in a single-dose (0.5 mL), pre-filled syringe.

Do not use PREVNAR 20 if:

- you or your child are allergic (hypersensitive) to the active substances or to any of the other ingredients in this vaccine, or to any other vaccine that contains diphtheria toxoid.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you or your child take PREVNAR 20. Talk about any health conditions or problems you or your child may have, including if you or your child:

- have any present or past medical problems after any dose of PREVNAR 20, PREVNAR 13 or PREVNAR, such as an allergic reaction or problems with breathing.
- have a severe illness or high fever. However, a mild fever or upper respiratory infection (for example having a cold) itself is not a reason to delay vaccination.
- have any bleeding problems or bruise easily.
- have a weakened immune system due to a medical condition or are on a medicine that affects your immune system. You/your child may not get the full benefit from PREVNAR 20.

If you or your child are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your healthcare professional for advice before receiving this vaccine.

Talk to your healthcare professional before the vaccination if your child is an infant and was born very prematurely (at or before 28 weeks of gestation) as longer gaps than normal between breaths may occur for 2-3 days after vaccination.

Other warnings you should know about:

As with any vaccine, PREVNAR 20 will not protect all persons who are vaccinated.

PREVNAR 20 has no or negligible influence on the ability to drive and use machines. However, some of the side effects mentioned under “What are possible side effects from using PREVNAR 20?” may temporarily affect the ability to drive or use machines.

Tell your healthcare professional about all the medicines you or your child take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Tell your healthcare professional if you or your child have been given a pneumococcal vaccine before, or have recently received any other vaccine.

Your child may be given PREVNAR 20 at the same time as other routine childhood vaccines.

In adults, PREVNAR 20 can be given at the same time as the flu (inactivated influenza) vaccine or the COVID-19 mRNA vaccine.

How to take PREVNAR 20:

A healthcare professional will inject the recommended dose (0.5 mL) of the vaccine into your upper arm, or your child’s upper arm or thigh muscle.

If you have any further questions on the use of PREVNAR 20, ask your healthcare professional.

Usual dose:Infants 6 Weeks to 15 Months of Age

Infants may receive 3 doses of the vaccine through 6 months of age. The first dose may be given from the age of 6 weeks, with doses given about 2 months apart. An additional dose is given to toddlers between 11 through 15 months of age. Your healthcare professional will tell you when your child should receive their next dose.

It is important to follow the instructions from your healthcare professional so that your child completes the course of vaccinations. If not, your child may not be fully protected from the disease.

Unvaccinated Children and Adolescents 7 Months Through 17 Years of Age

Children 7 months through 17 years of age who have never received a pneumococcal conjugate vaccine may receive PREVNAR 20 according to the following schedules:

- Infants 7 months through 11 months of age: 3 doses, with the first 2 doses given at least 4 weeks apart, and the third dose given after the 1st birthday
- Children 12 through 23 months of age: 2 doses, at least 2 months apart
- Children and adolescents 2 through 17 years of age: 1 dose

Previously Vaccinated Children and Adolescents 6 Through 17 Years of Age

Children and adolescents previously vaccinated with PREVNAR 13 may receive a single dose of PREVNAR 20.

Adults

You should receive one injection (0.5 mL dose) of the vaccine.

Special Populations

Individuals considered to be at a higher risk of pneumococcal infection (such as those with sickle cell disease or HIV infection), including those previously vaccinated with 23-valent pneumococcal polysaccharide vaccine, may receive at least 1 dose of PREVNAR 20.

Individuals with a blood-forming stem cell transplant may initially receive 3 doses, with the first dose given at 3 to 6 months after the transplant and with an interval of at least 4 weeks between doses. A fourth (booster) dose is recommended 6 months after the third dose.

Overdose:

Overdose with PREVNAR 20 is unlikely as it is supplied as a single-dose pre-filled syringe.

If you think you, or a person you are caring for, have taken too much PREVNAR 20, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If your child misses a dose, talk to your healthcare professional about what steps need to be taken to protect your child.

Possible side effects from using PREVNAR 20:

Like all vaccines, PREVNAR 20 can cause side effects, although not everybody gets them.

The following side effects include those reported for PREVNAR 20 in infants and children (6 weeks to less than 5 years of age):

Very common: may occur in more than 1 in 10 individuals

- Decreased appetite
- Irritability
- Feeling sleepy
- Fever
- At the injection site for all children: redness, swelling or hardness, pain or tenderness
- At the injection site after the booster dose and in children 2 to 5 years of age: redness, swelling or hardness greater than 2.0 to 7.0 cm

Common: may occur in more than 1 in 100 and up to 1 in 10 individuals

- Diarrhea
- Vomiting
- Rash
- Fever (38.9°C or higher)
- At the injection site after the initial course of injections: redness, hardness, swelling of greater than 2.0 to 7.0 cm

Uncommon: may occur in more than 1 in 1000 and up to 1 in 100 individuals

- Seizures (or fits), including those caused by a high temperature
- Hives (urticaria or urticaria-like rash)
- At the injection site: redness, swelling, or hardness of more than 7.0 cm; pain or tenderness interfering with movement

Rare: may occur with up to 1 in 1,000 individuals

- Injection site allergic (hypersensitivity) reaction

The following side effects include those reported for PREVNAR 20 in children and adolescents (5 through 17 years of age):

Very common: may occur in more than 1 in 10 individuals

- Headache
- Muscle pain
- At the injection site: pain, tenderness, redness, swelling or hardness.
- Tiredness

Common: may occur in more than 1 in 100 and up to 1 in 10 individuals

- Joint pain
- At the Injection site: pain or tenderness interfering with movement

Uncommon: may occur in more than 1 in 1000 and up to 1 in 100 individuals

- Hives (urticaria or urticaria-like rash)
- Fever

Children and adolescents with either HIV infection, sickle cell disease or a blood-forming stem cell transplant vaccinated with PREVNAR 13 had similar side effects, however, the frequencies of headache, vomiting, diarrhea, fever, fatigue, joint and muscle pain were very common (>1/10).

The following side effects include those reported for PREVNAR 20 in adults:

Common: may occur in more than 1 in 100 and up to 1 in 10 individuals

- Swelling/redness at injection site
- Fever (38°C or higher)

Uncommon: may occur in more than 1 in 1000 and up to 1 in 100 individuals

- Allergic reaction including swelling, shortness of breath, wheezing,
- Diarrhea, nausea and vomiting
- Rash and swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing
- Itching/hives at the injection site
- Swollen glands in the neck, armpit or groin
- Chills

The following side effects were seen with PREVNAR 13 in postmarketing experience and may also be seen with PREVNAR 20:

- Severe allergic reaction, shock or cardiovascular collapse; swelling of lips, face or throat (angioedema)
- Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination site, such as under the arm or in the groin
- At the injection site: hives (urticaria), redness and irritation (dermatitis) and itching (pruritus)
- A rash causing itchy red blotches (erythema multiforme)

These are not all the possible side effects you or your child may have when receiving PREVNAR 20. If you experience any side effects not listed here, tell your healthcare professional.

Tell your healthcare professional immediately if you or your child have symptoms of an allergic reaction, such as swelling of the face, lips, mouth tongue or throat, shortness of breath, or wheezing.

Reporting suspected side effects for vaccines

For the general public: Should you experience a side effect following immunization, please report it to your healthcare professional.

Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada (PHAC), Health Canada (HC), and Pfizer Canada ULC cannot provide medical advice.

For healthcare professionals: If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (<https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html>) and send it to your local Health Unit.

Storage:

Store in a refrigerator (2°C to 8 °C). PREVNAR 20 should be used as soon as possible after being removed from refrigeration.

Do not freeze. Discard if vaccine has been frozen.

Store syringes in the refrigerator horizontally (laying flat on shelf) to minimise the re-dispersion time.

Keep out of reach and sight of children.

Do not use this vaccine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Ask your pharmacist how to throw away any unused vaccine.

If you want more information about PREVNAR 20:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website [pfizer.ca]; or by calling 1-800-463-6001 (Pfizer Medical Information).

This leaflet was prepared by Pfizer Canada ULC.

Date of Authorization: September 29, 2025